Phibro Animal Health (PAHC) 10-K18 Sep 142014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Sep. 09, 2014	Sep. 09, 2014
	Jun. 30, 2014	Dec. 31, 2013	Class A common stock	Class B common stock
Entity Registrant Name	'PHIBRO ANIMAL HEALTH CORP	'	'	'
Entity Central Index Key	'0001069899	'	'	'
Entity Current Reporting Status	'Yes	'	'	'
Entity Voluntary Filers	'No	'	'	'
Current Fiscal Year End Date	'--06-30	'	'	'
Entity Filer Category	'Non-accelerated Filer	'	'	'
Entity Well-known Seasoned Issuer	'No	'	'	'
Entity Common Stock, Shares Outstanding	'	'	17,442,953	21,512,275
Entity Public Float	'	$0	'	'
Document Type	'10-K	'	'	'
Document Period End Date	30-Jun-14	'	'	'
Amendment Flag	'false	'	'	'
Document Fiscal Year Focus	'2014	'	'	'
Document Fiscal Period Focus	'FY	'	'	'

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Statement [Abstract]	'	'	'
Net sales	$691,914	$653,151	$654,101
Cost of goods sold	484,139	474,187	489,962
Gross profit	207,775	178,964	164,139
Selling, general and administrative expenses	143,981	122,233	114,814
Operating income	63,794	56,731	49,325
Interest expense	29,889	31,383	31,436
Interest expense, stockholders	3,192	4,388	4,264
Interest (income)	-119	-142	-281
Foreign currency (gains) losses, net	1,753	3,103	1,192
Loss on extinguishment of debt	22,771	'	'
Other (income) expense, net	'	151	-400
Income before income taxes	6,308	17,848	13,114
Provision (benefit) for income taxes	9,435	-7,043	6,138
Net income (loss)	($3,127)	$24,891	$6,976
Net income (loss) per share-basic and diluted (in dollars per share)	($0.10)	$0.82	$0.23
Weighted average common shares outstanding-basic and diluted (in dollars)	32,193	30,458	30,458
Dividends per share (in dollars per share)	$0.82	$0.10	'

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Statement of Comprehensive Income [Abstract]	'	'	'
Net income (loss)	($3,127)	$24,891	$6,976
Fair value of derivative instruments	1,025	-222	-841
Foreign currency translation adjustment	1,110	-5,968	-15,077
Unrecognized net pension gains (losses)	-4,423	5,390	-10,413
(Provision) benefit for income taxes	'	-2,016	'
Other comprehensive income (loss)	-2,288	-2,816	-26,331
Comprehensive income (loss)	($5,415)	$22,075	($19,355)

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
ASSETS	'	'
Cash and cash equivalents	$11,821	$27,369
Accounts receivable, net	113,858	99,137
Inventories, net	143,184	140,032
Prepaid expenses and other current assets	30,426	29,848
Total current assets	299,289	296,386
Property, plant and equipment, net	109,159	104,422
Intangibles, net	29,803	35,155
Other assets	34,072	38,179
Total assets	472,323	474,142
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Current portion of long-term debt	2,969	64
Accounts payable	59,608	57,902
Accrued expenses and other current liabilities	49,861	57,438
Total current liabilities	112,438	115,404
Revolving credit facility	'	34,000
Long-term debt	286,422	297,666
Long-term debt, stockholders	'	33,874
Other liabilities	58,314	62,136
Total liabilities	457,174	543,080
Commitments and contingencies (Note 13)	'	'
Common stock, par value $0.0001; 300,000,000 Class A shares authorized, 17,442,953 shares issued and outstanding; 30,000,000 Class B shares authorized, 21,348,600 shares issued and outstanding	4	7
Preferred stock, par value $0.0001; 16,000,000 shares authorized, no shares issued and outstanding	'	'
Paid-in capital	132,453	42,948
Accumulated deficit	-97,248	-94,121
Accumulated other comprehensive income (loss)	-20,060	-17,772
Total stockholders' equity (deficit)	15,149	-68,938
Total liabilities and stockholders' equity (deficit)	$472,323	$474,142

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Common stock, par value (in dollars per share)	'	$0.00
Common stock, shares authorized	'	200,000,000
Common stock, shares issued	'	30,458,220
Common stock, shares outstanding	'	30,458,220
Preferred stock, par value (in dollars per share)	$0.00	$1
Preferred stock, shares authorized	16,000,000	1,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Class A common stock	'	'
Common stock, par value (in dollars per share)	$0.00	'
Common stock, shares authorized	300,000,000	'
Common stock, shares issued	17,442,953	'
Common stock, shares outstanding	17,442,953	'
Class B common stock	'	'
Common stock, par value (in dollars per share)	$0.00	'
Common stock, shares authorized	30,000,000	'
Common stock, shares issued	21,348,600	'
Common stock, shares outstanding	21,348,600	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
OPERATING ACTIVITIES	'	'	'
Net income (loss)	($3,127)	$24,891	$6,976
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:	'	'	'
Depreciation and amortization	21,453	19,023	17,527
Amortization of deferred financing costs	1,021	1,366	1,418
Amortization of imputed interest and debt discount	427	560	327
Deferred income taxes	1,289	-12,035	-2,392
Foreign currency (gains) losses, net	1,429	2,887	3,414
Other	-538	-1,438	-482
Loss on extinguishment of debt	22,771	'	'
Payment of premiums and costs on extinguished debt	-17,205	'	'
Changes in operating assets and liabilities:	'	'	'
Accounts receivable, net	-14,683	-729	-3,775
Inventories, net	-3,186	-25,106	-745
Prepaid expenses and other current assets	-31	-6,526	-3,301
Other assets	5,103	-363	-5,792
Accounts payable	1,682	-6,601	6,410
Accrued interest	-13,813	33	-104
Accrued expenses and other liabilities	-3,304	5,475	12,507
Net cash provided (used) by operating activities	-712	1,437	31,988
INVESTING ACTIVITIES	'	'	'
Capital expenditures	-19,846	-19,947	-14,824
Business acquisitions	'	-18,692	-3,384
Other	434	281	465
Net cash provided (used) by investing activities	-19,412	-38,358	-17,743
FINANCING ACTIVITIES	'	'	'
Borrowings under the domestic senior and revolving credit facility	175,500	75,000	1,000
Repayments of the domestic senior and revolving credit facility	-209,500	-55,000	-4,500
Proceeds from long-term debt	289,275	'	'
Payments of long-term debt, capital leases and other	-335,374	-5,201	-4,718
Debt issuance costs	-4,551	-924	'
Proceeds from common stock issued	114,429	'	'
Dividends paid	-25,000	-3,000	'
Net cash provided (used) by financing activities	4,779	10,875	-8,218
Effect of exchange rate changes on cash	-203	-485	-725
Net increase (decrease) in cash and cash equivalents	-15,548	-26,531	5,302
Cash and cash equivalents at beginning of period	27,369	53,900	48,598
Cash and cash equivalents at end of period	11,821	27,369	53,900
Supplemental cash flow information	'	'	'
Interest paid	45,370	33,824	34,059
Income taxes paid, net	12,207	7,061	7,217
Non-cash investing and financing activities	'	'	'
Capital / leasehold improvements	1,315	'	1,569
Business acquisitions	'	4,550	3,000
Capital lease additions	$29	$103	$120

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Preferred Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
In Thousands, except Share data, unless otherwise specified	Common Stock	Preferred Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Jun. 30, 2011	$7	'	$42,538	($122,988)	$11,375	($69,068)
Balance (in shares) at Jun. 30, 2011	30,458,220	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Comprehensive income (loss)	'	'	'	6,976	-26,331	-19,355
Stock-based compensation expense	'	'	195	'	'	195
Balance at Jun. 30, 2012	7	'	42,733	-116,012	-14,956	-88,228
Balance (in shares) at Jun. 30, 2012	30,458,220	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Comprehensive income (loss)	'	'	'	24,891	-2,816	22,075
Dividends paid	'	'	'	-3,000	'	-3,000
Stock-based compensation expense	'	'	215	'	'	215
Balance at Jun. 30, 2013	7	'	42,948	-94,121	-17,772	-68,938
Balance (in shares) at Jun. 30, 2013	30,458,220	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Comprehensive income (loss)	'	'	'	-3,127	-2,288	-5,415
Issuance of common stock, net of issuance costs	1	'	114,428	'	'	114,429
Issuance of common stock, net of issuance costs (in shares)	8,333,333	'	'	'	'	'
Conversion of common stock certificate and effect of stock split	-4	'	4	'	'	'
Dividends paid	'	'	-25,000	'	'	-25,000
Stock-based compensation expense	'	'	73	'	'	73
Balance at Jun. 30, 2014	$4	'	$132,453	($97,248)	($20,060)	$15,149
Balance (in shares) at Jun. 30, 2014	38,791,553	'	'	'	'	'

Description_of_Business

Description of Business	12 Months Ended
Description of Business	Jun. 30, 2014
Description Of Business [Abstract]	'
Description of Business	'
	1
	Description of Business
	Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products to the poultry, swine, cattle, dairy, aquaculture and ethanol markets. The Company is also a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” “the Company” and similar expressions refer to Phibro and its subsidiaries.

Initial_Public_Offering_and_Re

Initial Public Offering and Refinancing	12 Months Ended
	Jun. 30, 2014
Initial Public Offering And Refinancing [Abstract]	'
Initial Public Offering and Refinancing	'
	2
	Initial Public Offering and Refinancing
	Initial Public Offering
	On April 16, 2014, we completed the initial public offering (“IPO”) of 14,657,200 shares of Class A common stock (including the exercise of the underwriters’ over-allotment option) at a price to the public of $15.00 per share. In connection with the IPO, we issued and sold 8,333,333 shares of Class A common stock. The proceeds to us from the IPO were $114,429, after deducting underwriting discounts of $8,438 and net offering expenses payable by us of $2,133.
	In connection with the IPO, Mayflower Limited Partnership (“Mayflower”), a limited partnership that is managed by 3i Investments plc and advised by 3i Corporation, and whose sole limited partner is 3i Group plc, the ultimate parent company of both 3i Investments plc and 3i Corporation, sold 6,323,867 shares of Class A common stock including 1,911,808 shares of Class A common stock pursuant to the exercise of the underwriters’ over-allotment option. We did not receive any proceeds from shares sold by Mayflower.
	In connection with the IPO, we effected a 0.442-for-1 stock split. All amounts have been adjusted retrospectively to give effect to the stock split.
	Issuance of Credit Facilities
	On April 16, 2014, Phibro, together with certain of its subsidiaries acting as guarantors, entered into a Credit Agreement with Bank of America, N.A. (“Bank of America”), as Administrative Agent, Collateral Agent and L/C Issuer, and each lender from time to time party thereto (the “Lenders”). The Lenders extended credit to the Company in the form of (i) a $290,000 Term B loan and (ii) a $100,000 revolving credit facility. The revolving credit facility was undrawn at closing and at June 30, 2014, and contains a letter of credit facility. See “—Debt.”
	Retirement of 9.25% Senior Notes, Mayflower Term Loan, BFI Term Loan and Domestic Senior Credit Facility
	On April 16, 2014, we retired a $24,000 term loan payable to Mayflower due December 31, 2016, a $10,000 term loan payable to BFI Co., LLC (“BFI”), a Bendheim family investment vehicle, due August 1, 2014 and $36,000 of outstanding borrowings under our domestic senior credit facility.
	On May 16, 2014, we retired $300,000 of 9.25% senior notes due July 1, 2018 (the “Senior Notes”).
	Effect of the Refinancing
	Our consolidated statement of operations for the year ended June 30, 2014, included a loss on extinguishment of debt as follows:

		Redemption premium on Senior Notes	$	17,184
		Write-off of original issue discount related to Senior Notes and BFI term loan		2,123
		Write-off of capitalized debt issuance costs related to Senior Notes, Mayflower term loan, BFI term loan and cancelled domestic senior credit facility and other items		3,464
		Loss on extinguishment of debt	$	22,771

Summary_of_Significant_Account

Summary of Significant Accounting Policies and New Accounting Standards	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies and New Accounting Standards	'
	3
	Summary of Significant Accounting Policies and New Accounting Standards
	Principles of Consolidation and Basis of Presentation
	The consolidated financial statements include the accounts of Phibro and all majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.
	We present our financial statements on the basis of our fiscal year ending June 30. All references to years in these consolidated financial statements refer to the fiscal year ending or ended on June 30 of that year.
	Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
	During the year ended June 30, 2014, we identified and corrected an error in prior period cash flows related to an equity method investment. We corrected the error and increased cash flows from operating activities and decreased cash flows from investing activities by $1,022 and $106 for 2013 and 2012, respectively. The error had no impact to the consolidated statements of operations, consolidated comprehensive income or the consolidated balance sheet. We have assessed the effects of the correction and have concluded the items were not material to our prior period consolidated financial statements. Accordingly we have revised the prior year statements of consolidated cash flows.
	During the quarter ended December 31, 2013, we identified and corrected errors that originated in prior periods. The error corrections increased income before income taxes by $358 in the current year. We have assessed the effects of the corrections and have concluded the items were not material, either individually or in aggregate, to our current year results of operations or any other prior period consolidated financial statements.
	Risks, Uncertainties and Liquidity
	An expansion of the regulatory restrictions on the use of antibiotics or antibacterials in food-producing animals could result in a decrease in our sales. The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on or banning of the use of antibiotics in food-producing animals. The sale of antibiotics and antibacterials is a material portion of our business. Should regulatory or other developments result in restrictions on the sale of such products, it could have a material adverse effect on our financial position, results of operations and cash flows.
	The testing, manufacturing, and marketing of certain of our products are subject to extensive regulation by numerous government authorities in the United States and other countries.
	We have significant assets in Israel, Brazil and other locations outside of the United States and a significant portion of our sales and earnings are attributable to operations conducted abroad. Our assets, results of operations and future prospects are subject to currency exchange fluctuations and restrictions, energy shortages, other economic developments, political or social instability in some countries, and uncertainty of, and governmental control over, commercial rights, which could result in a material adverse effect on our financial position, results of operations and cash flows.
	We are subject to environmental laws and regulations governing the use, storage, handling, generation, treatment, emission, release, discharge and disposal of certain materials and wastes, the remediation of contaminated soil and groundwater, the manufacture, sale and use of regulated materials, including pesticides, and the health and safety of employees. As such, the nature of our current and former operations and those of our subsidiaries expose Phibro and our subsidiaries to the risk of claims with respect to such matters.
	Use of Estimates
	Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Actual results could differ from these estimates. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, legal and environmental matters and actuarial assumptions related to our pension plans. We regularly evaluate our estimates and assumptions using historical experience and other factors. Our estimates are based on complex judgments, probabilities and assumptions that we believe to be reasonable.
	Revenue Recognition
	We recognize revenue upon transfer of title and when risk of loss passes to the customer. Certain of our businesses have terms of FOB shipping point where title and risk of loss transfer on shipment. Certain of our businesses have terms of FOB destination where title and risk of loss transfer on delivery. In the case of FOB destination, revenue is not recognized until products are received by the customer. Additional conditions for recognition of revenue are that persuasive evidence of an arrangement exists, the selling price is fixed or determinable, collections of sales proceeds are reasonably assured and we have no further performance obligations. We record estimated reductions to revenue for customer programs and incentive offerings, including pricing arrangements and other volume-based incentives, at the time the sale is recorded. Royalty and licensing income from licensing agreements are recognized when earned under the terms of the related agreements and are included in Net Sales in the consolidated statements of operations. Net Sales also include shipping and handling fees billed to customers. Delivery costs to our customers are included in cost of goods sold in the consolidated statements of operations.
	Cash and Cash Equivalents
	Cash equivalents include highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.
	Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are recorded at the invoiced amount and do not bear interest. We grant credit terms in the normal course of business and do not normally require collateral or other security to support credit sales. Our ten largest customers represented, in the aggregate, approximately 21% and 24% of accounts receivable at June 30, 2014 and 2013, respectively.
	The allowance for doubtful accounts is our best estimate of the probable credit losses in existing accounts receivable. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic conditions for the potential effect on our customers. Past due balances are reviewed individually for collectability. Bad debts have been minimal. Account balances are charged against the allowance when we determine it is probable the receivable will not be recovered.
	Inventories
	Inventories are valued at the lower of cost or market. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost. We capitalize interest expense as part of the cost of construction of facilities and equipment. No interest expense was capitalized in 2014, 2013 and 2012.
	Depreciation is charged to results of operations using the straight-line method based upon the assets’ estimated useful lives ranging from 8 to 25 years for buildings and improvements and 3 to 16 years for machinery and equipment.
	We capitalize costs that extend the useful life or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.
	Capitalized Software Costs
	We capitalize costs to obtain, develop and implement software for internal use in accordance with FASB Accounting Standards Codification (“ASC”) 350-40, Internal Use Software. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development. We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a straight-line basis over seven years.
	Deferred Financing Costs
	Costs and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the respective debt instruments. Amortization of deferred financing costs is included in interest expense in the consolidated statements of operations.
	Acquisitions, Intangible Assets and Goodwill
	Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition, with any excess of the purchase price over the fair values of the net assets acquired recorded as goodwill.
	Significant judgment is required to determine the fair value of certain tangible and intangible assets and in assigning their respective useful lives. Accordingly, we typically obtain the assistance of third-party valuation specialists for significant tangible and intangible assets. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product or technology life cycles, economic barriers to entry and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets are primarily based on a number of factors including competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations.
	Long-Lived Assets and Goodwill
	We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. An impairment loss would be recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded is calculated by the excess of the asset’s carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations. We have not experienced significant changes in the carrying value or estimated remaining useful lives of our long-lived or amortizable intangible assets in the periods included in the consolidated financial statements.
	We annually evaluate goodwill for impairment by comparing the book value to the fair value of the reporting unit to which the goodwill relates. If circumstances change significantly, we would also test a reporting unit’s goodwill for impairment during interim periods between its annual tests. We determine the fair value of the reporting units using a discounted cash flow analysis method. Considerable management judgment, such as assumptions of forecasted growth rates and discount rate, is necessary in arriving at the fair value. Application of alternative assumptions, such as changes in the estimate of future cash flows, could produce significantly different results. Because of the significance of the judgments and estimation processes, it is likely that different amounts could be recorded if we used different assumptions or if the underlying circumstances were to change. During the quarter ended June 30, 2014, we performed the annual goodwill impairment test and determined that none of the goodwill was impaired.
	Foreign Currency Translation
	We generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation adjustments that arise from the use of differing exchange rates from period to period are included in accumulated other comprehensive income (loss) in stockholders’ equity (deficit).
	Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from remeasurement of local currency accounts into U.S. dollars are included in determining net income or loss.
	Foreign currency gains and losses primarily arise from intercompany balances.
	Comprehensive Income (Loss)
	Comprehensive income (loss) consists of net income (loss) and the changes in: (i) the fair value of derivative instruments; (ii) foreign currency translation adjustment; (iii) unrecognized net pension gains (losses); and (iv) the related (provision) benefit for income taxes.
	Derivative Financial Instruments
	We record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or accumulated other
	comprehensive income (loss), depending on whether a derivative is designated and effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments reported in accumulated other comprehensive income (loss) are included in the results of operations in the periods in which operations are affected by the hedged item.
	From time to time, we use forward contracts and options to mitigate exposure to changes in foreign currency exchange rates and as a means of hedging forecasted operating costs. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. We hedge forecasted transactions for periods not exceeding the next twenty-four months. We do not engage in trading or other speculative uses of financial instruments.
	Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. ASC 820 uses a three level hierarchy to prioritize the inputs used in measuring fair value. Level 1 inputs include quoted prices in active markets for identical assets or liabilities. Level 2 inputs include observable inputs other than level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
	Environmental Liabilities
	Expenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companies’ experiences and data released by the U.S. Environmental Protection Agency or other organizations. The estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.
	Income Taxes
	The provision for income taxes includes U.S. federal, state, and foreign income taxes. Our annual tax rate is determined based on our income, statutory tax rates, the tax effects of items treated differently for tax purposes than for financial reporting purposes and tax planning opportunities available in the various jurisdictions in which we operate. Tax law requires certain items be included in the tax return at different times than the items are reflected in the consolidated financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences create deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our consolidated statements of operations. Deferred tax liabilities generally represent tax expense recognized in our consolidated financial statements for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our consolidated financial statements and assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.
	Significant judgment is required in determining our tax provision and in evaluating our tax positions. The recognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, primarily net operating loss carryforwards, is dependent upon generating sufficient taxable income in the appropriate jurisdiction prior to the expiration of the carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.
	We operate in multiple jurisdictions with complex tax policy and regulatory environments. In certain of these jurisdictions, we may take tax positions that management believes are supportable, but are potentially subject to successful challenge by the applicable taxing authority. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.
	Because there are a number of estimates and assumptions inherent in calculating the various components of our tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective tax rate.
	Research and Development Expenditures
	Research and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our manufacturing facilities have chemists and technicians on staff involved in product development, quality assurance, quality control and also providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. We operate animal health research and development facilities in Guarulhos, Brazil; Beit Shemesh, Israel; Naot Hovav, Israel; Quincy, Illinois; St. Paul, Minnesota; Corvallis, Oregon; and Manhattan, Kansas. These facilities provide research and development services relating to: fermentation development and micro-biological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional supplement development; and ethanol-related products.
	Stock-Based Compensation
	All stock-based compensation to employees, including grants of stock options, is expensed over the requisite service period based on the grant date fair value of the awards. We determine the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options.
	Net Income per Share and Weighted Average Shares
	Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.
Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the exercise of stock options and warrants. For the year ended June 30, 2014, there was a net loss; and we excluded 296,162 net shares of stock options and warrants from the calculation of diluted net income (loss) per share because of the anti-dilutive effect from the assumed exercise of these options and warrants. For the years ended June 30, 2013 and 2012, the stock options and warrants had an exercise price greater than the estimated market value and were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options and warrants was anti-dilutive.
New Accounting Standards
We have elected to adopt new accounting standards within the specified effective date established for public companies, where applicable.
Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, clarifies when it is appropriate for an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset. ASU 2013-11 was effective for interim and annual periods beginning after December 15, 2013. Early adoption is permitted. The guidance should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however, retrospective application is also permitted. We elected to early adopt the provisions of this pronouncement, and it did not have a material effect on our consolidated financial statements.
ASU 2014-08, Presentation of Financials (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, changes the criteria for reporting a discontinued operation while enhancing disclosures. Under the new guidance, a disposal of a component of an entity or group of components of an entity that represents a strategic shift that has, or will have, a major effect on operations and financial results is a discontinued operation when any of the following occurs: (i) it meets the criteria to be classified as held for sale, (ii) it is disposed of by sale, or (iii) it is disposed of other than by sale. Also, a business that, on acquisition, meets the criteria to be classified as held for sale is reported in discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations, as well as disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation. The guidance is effective prospectively for all disposals (or classifications as held for sale) of components of an entity and all businesses that, on acquisition, are classified as held for sale, that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2016. Early adoption is not permitted. The guidance should be applied retrospectively to each prior reporting period presented. We are currently evaluating the impact that adopting this guidance will have on our consolidated financial statements.
ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Management will need to assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will need to consider relevant conditions that are known and reasonably knowable at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Under the new standard, the definition of substantial doubt incorporates a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies. ASU 2014-15 will be effective for annual periods ending after December 15, 2016. Earlier adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.

Statements_of_OperationsAdditi

Statements of Operations-Additional Information	12 Months Ended
Statements of Operations-Additional Information	Jun. 30, 2014
Supplemental Income Statement Elements [Abstract]	'
Statements of Operations-Additional Information	'

	4
	Statements of Operations—Additional Information

		For the Years Ended June 30	2014			2013			2012
		Depreciation and amortization
		Depreciation of property, plant and equipment		$	16,439		$	14,917		$	14,425
		Amortization of intangible assets			4,897			4,106			3,048
		Amortization of other assets			117			—			54
		Depreciation and amortization		$	21,453		$	19,023		$	17,527


	Depreciation of property, plant and equipment includes amortization of capitalized software costs of $2,657, $2,159 and $2,362 during 2014, 2013 and 2012, respectively.
	Amortization of intangible assets is expected to be $4,210, $3,699, $2,864, $2,691, $2,656 and $13,683 for 2015, 2016, 2017, 2018, and 2019 and thereafter, respectively.

		Research and development expenditures		$	8,212		$	6,638		$	7,189

Balance_SheetsAdditional_Infor

Balance Sheets-Additional Information	12 Months Ended
Balance Sheets-Additional Information	Jun. 30, 2014
Balance Sheets Additional Information [Abstract]	'
Balance Sheets-Additional Information	'

	5. Balance Sheets—Additional Information


		As of June 30			2014						2013
		Accounts receivable, net
		Trade accounts receivable				$	115,093					$	99,795
		Allowance for doubtful accounts					(1,235	)					(658	)
						$	113,858					$	99,137
		Allowance for doubtful accounts(1)
		Balance at beginning of period				$	658					$	1,041
		Provision for bad debts					226						(124	)
		Effect of changes in exchange rates					351						(265	)
		Bad debt write-offs (recovery)					—						6
		Balance at end of period				$	1,235					$	658



	-1
	For the year ended June 30, 2012, the beginning balance for allowance for doubtful accounts was $1,029, the provision for bad debts was ($115) and the effect of changes in exchange rates was $127, resulting in an ending balance for allowance for doubtful accounts of $1,041.

		As of June 30			2014						2013
		Inventories, net
		Raw materials				$	44,306					$	36,589
		Work-in-process					7,518						7,541
		Finished goods					91,360						95,902
						$	143,184					$	140,032
		Property, plant and equipment, net
		Land				$	9,773					$	9,746
		Buildings and improvements					51,364						46,960
		Machinery and equipment					172,530						156,247
							233,667						212,953
		Accumulated depreciation					(124,508	)					(108,531	)
						$	109,159					$	104,422


	Certain facilities in Israel are on land leased for a nominal amount from the Israel Land Authority. The lease expires July 9, 2027. Certain facilities in Israel are on leased land. The lease expires November 30, 2035.
	Net equipment under capital leases was $142 and $152 at June 30, 2014 and 2013, respectively, including accumulated depreciation of $79 and $39, respectively.
	Property, plant and equipment, net includes internal-use software costs, net of accumulated depreciation, of $9,019 and $9,154 at June 30, 2014 and 2013, respectively.
	Machinery and equipment includes construction-in-progress of $4,782 and $5,543 at June 30, 2014 and 2013, respectively.

		As of June 30			Weighted-						2014				2013
					Average
					Useful Life
					(Years)
		Intangibles, net
		Cost
		Medicated feed additive product registrations					10					$	11,792			$	12,115
		Rights to sell in international markets					10						4,292				4,292
		Customer relationships					13						10,702				10,691
		Technology					11						28,259				28,259
		Distribution agreements					4						3,447				3,493
		Trade names, trademarks and other					5						2,740				2,740
													61,232				61,590
		Accumulated amortization
		Medicated feed additive product registrations											(11,039	)			(10,778	)
		Rights to sell in international markets											(4,292	)			(3,861	)
		Customer relationships											(4,265	)			(3,203	)
		Technology											(6,510	)			(3,729	)
		Distribution agreements											(3,309	)			(3,179	)
		Trade names, trademarks and other											(2,014	)			(1,685	)
													(31,429	)			(26,435	)
												$	29,803			$	35,155


	As of June 30			2014						2013
	Other assets
	Goodwill				$	12,613					$	12,613
	Advances to and investments in equity method investees					5,619						3,515
	Insurance investments					4,626						4,456
	Deferred financing fees					5,199						5,212
	Deferred income taxes					3,486						4,755
	Insurance claim receivable					—						5,350
	Other					2,529						2,278
					$	34,072					$	38,179


We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $5,140 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.
As of June 30			2014						2013
	Goodwill roll-forward
	Balance at beginning of period				$	12,613					$	1,717
	OGR acquisition					—						10,896
	Balance at end of period				$	12,613					$	12,613
	Accrued expenses and other current liabilities
	Employee related accruals				$	20,813					$	17,823
	Interest					—						13,875
	Commissions and rebates					2,973						3,196
	Insurance related					1,395						1,286
	Professional fees					4,229						4,064
	Deferred consideration on acquisitions					1,420						1,250
	Product liability claims					5,286						—
	Other accrued liabilities					13,745						15,944
					$	49,861					$	57,438
	Other liabilities
	Pension and other retirement benefits				$	31,025					$	26,021
	Long term and deferred income taxes					14,282						17,580
	Deferred consideration on acquisitions					2,879						5,009
	Product liability claims					—						5,600
	Other long term liabilities					10,128						7,926
					$	58,314					$	62,136


	As of June 30			2014						2013
	Accumulated other comprehensive income (loss)
	Derivative instruments				$	386					$	(639	)
	Foreign currency translation adjustment					(1,409	)					(2,519	)
	Unrecognized net pension gains (losses)					(16,663	)					(12,240	)
	Income tax (provision) benefit on derivative instruments					63						63
	Income tax (provision) benefit on pension gains (losses)					(2,437	)					(2,437	)
					$	(20,060	)				$	(17,772	)

Acquisition

Acquisition	12 Months Ended
Acquisition	Jun. 30, 2014
Business Combinations [Abstract]	'
Acquisition	'
	6
	Acquisition
	On December 20, 2012, Prince Agri Products, Inc. (“Prince Agri”), a subsidiary of Phibro, acquired 100% of the membership interests of OmniGen Research, LLC (“OGR”). We acquired all rights to OmniGen-AF patents and related intellectual property and certain property, plant and equipment. OmniGen-AF is a proprietary nutritional specialty product that helps maintain a dairy cow’s healthy immune system. Prior to the transaction, Prince Agri had been the exclusive manufacturer and marketer of OmniGen-AF for 9 years, under a licensing arrangement with OGR.
	The purchase price was $22,750, with an initial cash payment of $18,500 and deferred payments of $4,250. We paid $1,000 in December 2013. Annual deferred payments of $1,000 are due on or before December 20, 2014 and 2015. A final deferred payment of $1,250 is due on or before December 20, 2016. Interest is accrued and payable solely on the final installment at the rate of 5% annually from December 20, 2012 to the date of payment.
	The results of the business have been included in the consolidated statements of operations since the date of acquisition. Acquired identifiable intangibles are amortized over the remaining 12-year life of the principal patents acquired. The allocation of the purchase price was:

		Assets
		Property, plant and equipment		$	1,202
		Intangibles			23,781
		Goodwill			10,896
		Total assets		$	35,879
		Liabilities
		Other current and long-term liabilities		$	13,129
		Total liabilities			13,129
		Net assets acquired		$	22,750


	In accordance with ASC 805, the excess of the purchase price over the fair values of the net assets acquired was recorded as goodwill. The goodwill is not deductible for U.S. federal or state income taxes.
	OGR’s only revenues were the royalties paid by Prince Agri. As a result, our operating results benefited from the elimination of the royalties previously paid to OGR, net of operating expenses related to acquired research and development activities. The unaudited pro forma consolidated results of operations, as if such acquisition had occurred at the beginning of the fiscal year ended June 30, 2012, are as follows:

		For the Years Ended June 30	2013			2012
		Net sales		$	653,151		$	654,101
		Net income (loss)			25,989			9,170
		Net income (loss) per share−basic and diluted			0.85			0.3
		Adjusted EBITDA			77,731			70,804

Debt

Debt	12 Months Ended
Debt	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	7
	Debt
	Revolving Credit Facility and Term B Loan
	On April 16, 2014, Phibro, together with certain of its subsidiaries acting as guarantors, entered into a Credit Agreement (the “Credit Agreement”) with Bank of America, N.A. (“Bank of America”), as Administrative Agent, Collateral Agent and L/C Issuer, and each lender from time to time party thereto (the “Lenders”). Under the Credit Agreement, the Lenders agreed to extend credit to the Company in the form of (i) a Term B loan in an aggregate principal amount equal to $290,000 (the “Term B Loan”) and (ii) a revolving credit facility in an aggregate principal amount of $100,000 (the “Revolving Credit Facility,” and together with the Term B Loan, the “Credit Facilities”). The Revolving Credit Facility was undrawn at closing and contains a letter of credit facility.
	Borrowings under the Credit Facilities bear interest based on a fluctuating rate equal to the sum of an applicable margin and, at the Company’s election from time to time, either (1) a Eurocurrency rate determined by reference to LIBOR with a term as selected by the Company, of one day or one, two, three or six months (or twelve months or any shorter amount of time if consented to by all of the lenders under the applicable loan), or (2) a base rate determined by reference to the highest of (a) the rate as publicly announced from time to time by Bank of America as its “prime rate,” (b) the federal funds effective rate plus 0.50% and (c) one-month LIBOR plus 1.00%. The Revolving Credit Facility has applicable margins equal to 1.50% or 1.75%, in the case of base rate loans, and 2.50% or 2.75%, in the case of LIBOR loans; the margins are based on the First Lien Net Leverage Ratio. The Term B Loan has applicable margins equal to 2.00%, in the case of base rate loans, and 3.00%, in the case of LIBOR loans. Interest on the Term B Loan is subject to a floor of 1.00% in the case of LIBOR loans.
	Indebtedness under the Credit Facilities is collateralized by a first priority lien on substantially all assets of Phibro and certain of our domestic subsidiaries. The Term B Loan requires, among other things, mandatory quarterly principal payments of $725 beginning September 2014. The maturity dates of the Revolving Credit Facility and the Term B Loan are April 15, 2019 and April 15, 2021, respectively.
	We issued the Term B Loan at 99.75% of par value, with proceeds of $284,740, after deducting $5,260 of original issue discount and costs related to the issuance of these facilities.
	As of June 30, 2014, we had no outstanding borrowings under the Revolving Credit Facility and had outstanding letters of credit and other commitments of $17,140, leaving $82,860 available for borrowings and letters of credit under the Revolving Credit Facility.
	We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year.
	The Credit Facilities contains various covenants which, among other things and subject to the permitted exceptions described therein, restrict us and our subsidiaries with respect to: (i) incurring additional debt; (ii) making certain restricted payments or making optional redemptions of other indebtedness; (iii) making investments or acquiring assets; (iv) disposing of assets (other than in the ordinary course of business); (v) creating any liens on our assets; (vi) entering into transactions with affiliates; (vii) entering into merger or consolidation transactions; and (viii) creating guarantee obligations; provided, however, that we are permitted to pay distributions to stockholders out of available cash subject to certain annual limitations and so long as no default or event of default under the Credit Facilities shall have occurred and be continuing at the time such distribution is declared.
	The Revolving Credit Facility requires, among other things, the maintenance of a maximum consolidated first lien net debt to consolidated EBITDA leverage ratio, calculated on a trailing four quarter basis, and contains an acceleration clause should an event of default (as defined in the agreement) occur. The permitted maximum ratio is 4.50:1.00 for measurement periods beginning September 30, 2014 through June 30, 2015 and 4.25:1.00 for measurements periods thereafter. As of June 30, 2014, we were in compliance with the covenants of the Credit Facilities.
	Long-Term Debt

		As of June 30	2014				2013
		Term B loan due April 15, 2021		$	290,000			$	—
		Senior notes due July 1, 2018			—				300,000
		Term loan payable to Mayflower due December 31, 2016			—				24,000
		Term loan payable to BFI due August 1, 2014			—				10,000
		Capitalized lease obligations			94				132
					290,094				334,132
		Unamortized debt discount			(703	)			(2,528	)
					289,391				331,604
		Less: current maturities			(2,969	)			(64	)
				$	286,422			$	331,540


	Foreign Bank Loans
	Our Israel subsidiaries have aggregate credit facilities available of approximately $15 million (the “Israel Credit Facility”). As of June 30, 2014, we had no outstanding borrowings or other commitments outstanding under the Israel Credit Facility. Interest rate elections under the Israel Credit Facility are LIBOR plus 2.25% or Prime Rate plus 1.00%. The Israel Credit Facility matures on December 31, 2014.
	Aggregate Maturities of Long-Term Debt

		For the Years Ended June 30
		2015	$2,969
		2016	2,918
		2017	2,907
		2018	2,900
		2019	2,900
		Thereafter	275,500
		Total	$290,094

Preferred_Stock_Common_Stock_W

Preferred Stock, Common Stock, Warrant and Dividends	12 Months Ended
Preferred Stock, Common Stock, Warrant and Dividends	Jun. 30, 2014
Equity [Abstract]	'
Preferred Stock, Common Stock, Warrant and Dividends	'
	8
	Preferred Stock, Common Stock, Warrant and Dividends
	Preferred stock and common stock at June 30, 2014 and 2013, after giving effect to the 0.442-for-1 stock split, were:

			2014		2013					2014		2013
		As of June 30	Authorized shares				Par value			Issued and outstanding shares
		Preferred stock		16,000,000		—		$	0.0001		—		—
		Common stock−Class A		300,000,000		—		$	0.0001		17,442,953		—
		Common stock−Class B		30,000,000		—		$	0.0001		21,348,600		—
		Preferred stock		—		1,000,000		$	1		—		—
		Common stock		—		200,000,000		$	0.0001		—		30,458,220


	Common Stock and Common Stock Warrant
	Class A Common Stock
	Holders of our Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Except as otherwise provided by our amended and restated certificate of incorporation or applicable law, the holders of our Class A common stock and Class B common stock shall vote together as a single class. There are no cumulative voting rights.
	Holders of our Class A common stock are entitled to receive dividends when and if declared by our Board of Directors out of funds legally available therefore and pro rata with holders of our Class B common stock, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock.
	Upon our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our Class A common stock will be entitled to receive pro rata with holders of our Class B common stock our remaining assets available for distribution.
	Holders of our Class A common stock do not have preemptive, subscription or conversion rights. Our Class A common stock is not convertible and there are no redemption or sinking fund provisions applicable to our Class A common stock. Unless our Board of Directors determines otherwise, we will issue all of our capital stock in uncertificated form.
	Holders of approximately 2.8 million shares of our Class A common stock will have the right to require us to register the sales of their shares under the Securities Act, under the terms of agreements between us and the holders of these securities.
	Class B Common Stock
	All of our outstanding Class B common stock is held by BFI. Holders of our Class B common stock are entitled to 10 votes for each share held of record on all matters submitted to a vote of stockholders. Except as otherwise provided by our amended and restated certificate of incorporation or applicable law, the holders of our Class A common stock and Class B common stock shall vote together as a single class. There are no cumulative voting rights.
	Holders of our Class B common stock are entitled to receive dividends when and if declared by our Board of Directors out of funds legally available therefore and pro rata with holders of our Class A common stock, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock.
	Upon our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our Class B common stock will be entitled to receive pro rata with holders of our Class A common stock our remaining assets available for distribution.
	Holders of our Class B common stock do not have preemptive or subscription rights. There are no redemption or sinking fund provisions applicable to our Class B common stock.
	Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, except for certain transfers by and among BFI, its affiliates and certain Bendheim family members, as described in the amended and restated certificate of incorporation. Once transferred and converted into Class A common stock, the Class B common stock will not be reissued. In addition, all shares of Class B common stock will automatically convert to shares of Class A common stock when the outstanding shares of Class B common stock and Class A common stock held by BFI, its affiliates and certain Bendheim family members, together, is less than 15% of the total outstanding shares of Class A common stock and Class B common stock, taken as a single class.
	Holders of approximately 21.5 million shares of our Class B common stock, which includes shares of our Class B common stock issued pursuant to the automatic exercise of a warrant on August 1, 2014, will have the right to require us to register the sales of their shares under the Securities Act, under the terms of agreements between us and the holders of these securities.
	Class B Common Stock Warrant
	On August 1, 2014, a common stock purchase warrant for the purchase of 386,750 shares of Class B common stock, held by BFI, was automatically exercised. BFI paid the exercise price of $11.83 per share on a cashless basis, resulting in a net issuance of 163,675 shares of Class B common stock to BFI.
	Preferred Stock
	We do not have any preferred stock outstanding. Our Board of Directors has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the General Corporation Law of the State of Delaware. The issuance of our preferred stock could have the effect of decreasing the trading price of our Class A common stock, restricting dividends on our capital stock, diluting the voting power of our Class A common stock, impairing the liquidation rights of our capital stock, or delaying or preventing a change in control of the Company.
	Dividends
	We intend to pay regular quarterly dividends to holders of our Class A and Class B common stock out of assets legally available for this purpose. In July 2014, we declared a $0.10 per share dividend to holders of record as of September 3, 2014 of our Class A and Class B common stock, payable September 24, 2014. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.

Stock_Option_Plan

Stock Option Plan

12 Months Ended

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plan

On March 12, 2008, our Board of Directors and stockholders adopted the 2008 Incentive Plan (the “Incentive Plan”). The Incentive Plan provides directors, officers, employees and consultants to the Company with opportunities to purchase common stock pursuant to options that may be granted, and receive grants of restricted stock and other stock-based awards granted, from time to time by the Board of Directors or a committee approved by the Board. The Incentive Plan provides for grants of stock options, stock awards and other incentives for up to 6,630,000 shares. There were 5,131,620 Class A shares available for grant pursuant to the Incentive Plan as of June 30, 2014.

On February 26, 2009 and April 29, 2013, PAHC’s Compensation Committee awarded stock options with an exercise price of $11.83 per share, pursuant to the Incentive Plan. In connection with the grants, we obtained third party valuation reports and determined that the exercise price per share was not less than the fair value of the common stock at the grant date. The weighted-average grant-date fair value of stock options was $0.99. The awards granted were non-qualified stock options that vested at various dates through March 1, 2014. The options expire February 28, 2019. All stock options are exercisable for Class A common stock.

The Company recognizes compensation expense for the options over the vesting period in selling, general and administrative expenses. As of June 30, 2014, there was no unrecognized compensation expense.

Options

Weighted-

Average

Exercise Price

Per Share

Outstanding, June 30, 2013

1,498,380

11.83

Granted

—

Exercised

—

Forfeited or expired

—

Outstanding, June 30, 2014

1,498,380

11.83

Exercisable, June 30, 2014

1,498,380

11.83

All options were fully vested and exercisable at June 30, 2014, including 374,595 shares that vested during fiscal year 2014. Outstanding and exercisable options at June 30, 2014, had a $15,164 aggregate intrinsic value, based on the market price of Phibro stock as of that date, less the exercise price.

The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. The Black-Scholes model required several assumptions including:

2013

Risk-free rate of return

2.70%

Expected life

3.0 to 7.5 years

Expected volatility

35%−50%

Expected dividend yield

0.00%

The risk-free rate of return is based on U.S. treasury rates as of the grant date. The expected life is based on historical turnover rates by employee classification. Expected volatility is estimated based on implied volatility and a comparison to similar publicly traded companies in similar industries. At the dates of the grants, the expected dividend yield assumed the Company would not pay dividends for the expected life of the options.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	10
	Related Party Transactions
	The Mayflower term loan and the BFI term loan were related party transactions.
	Certain relatives of Mr. Bendheim provided services to us as employees or consultants and received aggregate compensation and benefits of approximately $1,764, $1,858 and $1,655 for 2014, 2013 and 2012, respectively.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	11
	Employee Benefit Plans
	The Company maintains a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. Plan benefits are based upon years of service and average compensation, as defined. The measurement dates for the pension plan were as of June 30, 2014, 2013 and 2012.
	Changes in the projected benefit obligation, plan assets and funded status were:

		For the Years Ended June 30		2014							2013
		Change in projected benefit obligation
		Projected benefit obligation at beginning of year			$	46,569						$	46,811
		Service cost				2,457							2,729
		Interest cost				2,333							2,058
		Benefits paid				(1,092	)						(796	)
		Actuarial (gain) loss				7,332							(4,233	)
		Projected benefit obligation at end of year			$	57,599						$	46,569


		For the Years Ended June 30		2014							2013
		Change in plan assets
		Fair value of plan assets at beginning of year			$	31,501						$	27,856
		Actual return on plan assets				4,339							1,888
		Employer contributions				4,833							2,553
		Benefits paid				(1,092	)						(796	)
		Fair value of plan assets at end of year			$	39,581						$	31,501
		Funded status at end of year			$	(18,018	)					$	(15,068	)


	The funded status is included in other liabilities in the consolidated balance sheets. At June 30, 2014 and 2013, the accumulated benefit obligation was $51,980 and $41,859, respectively.
	The Company expects to contribute approximately $6,815 to the pension plan during 2015. We seek to maintain an asset balance that meets the long-term funding requirements identified by actuarial projections while also satisfying ERISA fiduciary responsibilities.
	Accumulated other comprehensive (income) loss related to the pension plan was:

		For the Years Ended June 30		2014							2013
		Balance at beginning of period			$	12,240						$	17,630
		Amortization of net actuarial loss (gain) and prior service costs				(903	)						(1,405	)
		Current period net actuarial loss (gain)				5,326							(3,985	)
		Net change				4,423							(5,390	)
		Balance at end of period			$	16,663						$	12,240


	Amortization of unrecognized net actuarial (gain) loss and prior service costs will be approximately $1,228 during 2015.
	Net periodic pension expense was:

		For the Years Ended June 30		2014							2013							2012
		Service cost−benefits earned during the year			$	2,457						$	2,729						$	2,093
		Interest cost on benefit obligation				2,333							2,058							1,957
		Expected return on plan assets				(2,334	)						(2,136	)						(2,040	)
		Amortization of net actuarial loss and prior service costs				904							1,405							251
		Net periodic pension expense			$	3,360						$	4,056						$	2,261


	Significant actuarial assumptions for the plan were:

		For the Years Ended June 30		2014			2013			2012
		Discount rate for service and interest		5.00%			4.40%			5.50%
		Expected rate of return on plan assets		7.00%			7.50%			7.50%
		Rate of compensation increase		3.0%−4.5%			3.0%−4.5%			3.0%−4.5%
		Discount rate for year-end benefit obligation		4.50%			5.00%			4.40%


	The plan used the Aon Hewitt AA Bond Universe as a benchmark for its discount rate as of June 30, 2014, 2013 and 2012. The discount rate is determined by matching the pension plan’s timing and the amount of expected cash outflows to a bond yield curve constructed from a population of AA-rated corporate bond issues which are generally non-callable and have at least $250 million par value outstanding. From this, the discount rate that results in the same present value is calculated.
	Estimated future benefit payments, including benefits attributable to future service, are:

		For the Years Ended June 30
		2015			$	1,423
		2016				1,655
	2017				1,891
	2018				2,119
	2019				2,362
	2020−2024				15,973


The plan’s target asset allocations for 2015 and the weighted-average asset allocation of plan assets as of June 30, 2014 and 2013 are:

			Target			Percentage of Plan Assets
			Allocation			Percentage of Plan Assets
	For the years ended June 30		2015			2014							2013
	Debt securities		10%−35%					20	%						25	%
	Equity securities		20%−50%					35	%						70	%
	Global asset allocation/risk parity(1)		20%−40%					35	%						—
	Other		0%−25%					10	%						5	%



-1
The global asset allocation/risk parity category consists of a variety of asset classes including, but not limited to, global bonds, global equities, real estate, commodities and alpha only strategies.
The expected long-term rate of return for the plan’s total assets is generally based on the plan’s asset mix. In determining the rate to use, we consider the expected long-term real returns on asset categories, expectations for inflation, estimates of the effect of active management and actual historical returns.
The investment policy and strategy is to earn a long term investment return sufficient to meet the obligations of the plans, while assuming a moderate amount of risk in order to maximize investment return. In order to achieve this goal, assets are invested in a diversified portfolio consisting of equity securities, debt securities, and other investments in a manner consistent with ERISA’s fiduciary requirements.
The fair values of the Company’s plan assets by asset category were:

			Fair Value Measurements Using
	As of June 30, 2014		Level 1							Level 2							Level 3					Total
	Cash and cash equivalents			$	138						$	—						$	—				$	138
	Common-collective funds
	Global large cap equities				—							9,909							—					9,909
	Fixed income securities				—							3,935							—					3,935
	Global asset allocations/risk parity				—							5,803							—					5,803
	Mutual funds
	Global Equities				3,925							—							—					3,925
	Fixed income securities				1,913							—							—					1,913
	Global asset allocations/risk parity				3,927							—							—					3,927
	Other
	Fixed income securities				—							—							2,007					2,007
	Global asset allocations/risk parity				—							—							3,954					3,954
	Other				—							—							4,070					4,070
				$	9,903						$	19,647						$	10,031				$	39,581



			Fair Value Measurements Using
	As of June 30, 2013		Level 1							Level 2							Level 3					Total
	Cash and cash equivalents			$	581						$	404						$	—				$	985
	Common-collective funds
	Global large cap equities				6,555							4,743							—					11,298
	Fixed income securities				—							6,730							—					6,730
	Mutual funds
	Global small and mid-cap equities				10,887							—							—					10,887
	Real estate				1,320							—							—					1,320
	Other				—							—							280					280
				$	19,343						$	11,877						$	280				$	31,500


The table below provides a summary of the changes in the fair value of Level 3 assets:

	Change in Fair Value Level 3 assets		2014							2013
	Balance at beginning of period			$	280						$	450
	Redemptions				22							—
	Purchases				9,773							51
	Change in fair value				(44	)						(221	)
	Balance at end of period			$	10,031						$	280


The following outlines the valuation methodologies used to estimate the fair value of our pension plan assets:
•
Cash and cash equivalents are valued at $1 per unit;
•
Common-collective funds are determined based on current market values of the underlying assets of the fund;
•
Mutual funds and foreign currency deposits are valued using quoted market prices in active markets; and
•
For Level 3 managed assets, business appraisers use a combination of valuations and appraisal methodologies, as well as a number of assumptions to create a price which brokers evaluate. For Level 3 non-managed assets, pricing is provided by various sources, such as issuer or investment manager.
Our consolidated balance sheets include other liabilities of $13,007 and $10,953 as of June 30, 2014 and 2013, respectively, for other retirement benefits, including supplemental executive retirement benefits, international retirement plans and other employee benefit plans. Contributions to these plans are generally deposited under fiduciary-type arrangements. Expense under these plans was $3,832, $2,817 and $3,163 for 2014, 2013 and 2012, respectively.
We provide a 401(k) retirement savings plan, under which United States employees may make a pre-tax contribution of up to the lesser of 60% of compensation or the maximum amount permitted under the U.S. Internal Revenue Code. We make a matching contribution equal to 100% of the first 1% of an employee’s contribution and make a matching contribution equal to 50% of the next 5% of an employee’s contribution. Employees hired on or after January 1, 2014, receive a non-elective Company contribution of 3% and are eligible to receive an additional discretionary payment between 1% and 4%, depending on age and years of service, provided that such payments comply with mandatory non-discrimination testing. Participants are fully vested in employer contributions after two years of service. Our contribution expense was $1,281, $1,175 and $1,010 in 2014, 2013 and 2012, respectively.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	12
	Income Taxes
	Income (loss) before income taxes was:

		For the Years Ended June 30		2014					2013					2012
		Domestic			$	(26,226	)			$	(6,581	)			$	(10,002	)
		Foreign				32,534					24,429					23,116
		Income (loss) before income taxes			$	6,308				$	17,848				$	13,114


	Components of the provision for income taxes were:

		For the Years Ended June 30		2014					2013					2012
		Current provision (benefit):
		Federal			$	(673	)			$	—				$	66
		State and local				(268	)				391					219
		Foreign				9,087					4,487					7,555
		Total current provision				8,146					4,878					7,840
		Deferred provision (benefit):
		Federal				(1,632	)				(12,160	)				(6,282	)
		State and local				(1,877	)				(616	)				(1,275	)
		Foreign				966					(1,204	)				(290	)
		Change in valuation allowance−domestic				3,509					1,704					7,557
		Change in valuation allowance−foreign				323					355					(1,412	)
		Total deferred provision				1,289					(11,921	)				(1,702	)
		Provision (benefit) for income taxes			$	9,435				$	(7,043	)			$	6,138


	Reconciliations of the Federal statutory rate to the Company’s effective tax rate were:

		For the Years Ended June 30		2014					2013					2012
		Federal income tax rate				35	%				35	%				35	%
		State and local taxes, net of federal income tax effect				(0.9	)				1.4					1.1
		Foreign tax rate differential, and change in foreign				(91.0	)				(31.4	)				(33.0	)
		valuation allowance				(91.0	)				(31.4	)				(33.0	)
		Foreign withholding tax				36.5					1.4					2
		Change in federal valuation allowance				43.6					7.8					47.9
		OGR acquisition adjustment				—					(50.7	)				—
		Change in unrecognized tax benefits				(34.9	)				5.4					8.3
		Taxable income not recorded on books				—					0.6					2.4
		Repatriation of foreign earnings				138.7					—					—
		Permanent items				26.1					(7.9	)				(16.1	)
		Other				(3.5	)				(1.1	)				(0.8	)
		Effective tax rate				149.6	%				(39.5	)%				46.8	%


	We have not provided for United States or additional foreign taxes on approximately $93,622 of undistributed earnings of foreign subsidiaries, which earnings have been or are intended to be reinvested. It is not practicable at this time to determine the amount of income tax liability that would result should such earnings be repatriated. Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
	We assert our intention to indefinitely reinvest foreign earnings outside of the United States. During 2014, we reviewed the ongoing cash needs of our foreign subsidiaries and determined $25,000 was not needed for reinvestment in our Israel subsidiary. Based on this review, we changed the indefinite reinvestment assertion solely with respect to those earnings, and recorded $3,160 of foreign withholding taxes in the provision for income taxes. Our Israel subsidiary paid a $25,000 dividend to Phibro in 2014.
	The tax effects of significant temporary differences that comprise deferred tax assets and liabilities were:

		As of June 30		2014					2013
		Deferred tax assets:
		Employee related accruals			$	12,417				$	10,709
		Environmental remediation				2,306					2,348
		Net operating loss carry forwards−domestic				19,183					18,790
		Net operating loss carry forwards−foreign				8,729					9,860
		Other				9,540					8,413
						52,175					50,120
		Valuation allowance				(32,892	)				(27,753	)
						19,283					22,367
		Deferred tax liabilities:
		Property, plant and equipment and intangible assets				(13,428	)				(14,645	)
		Unrealized foreign exchange gains				(4,680	)				(4,827	)
	Other				(131	)				(573	)
					(18,239	)				(20,045	)
	Net deferred tax asset (liability)			$	1,044				$	2,322


Deferred taxes are included in the consolidated balance sheets as follows:

	As of June 30		2014					2013
	Prepaid expenses and other current assets			$	3,242				$	2,294
	Accrued expenses and other current liabilities				(1,626	)				(1,732	)
	Other assets				3,486					4,755
	Other liabilities				(4,058	)				(2,995	)
				$	1,044				$	2,322


The authoritative guidance for accounting for income taxes requires that a valuation allowance be established when it is “more likely than not” that all or a portion of the deferred tax assets will not be realized. All available positive and negative evidence are required to be considered, including a company’s performance, the market environment in which the company operates, the utilization of past tax credits, and length of carryback and carryforward periods. The authoritative guidance further states that where there is negative evidence such as cumulative losses in recent years, concluding that a valuation allowance is not required is problematic. Therefore, cumulative losses weigh heavily in the overall assessment.
Management has determined that it is not more likely than not that the Company would be able to utilize certain deferred tax assets. This conclusion was reached due to cumulative losses recognized by the Company and certain subsidiaries in preceding years. Management intends to maintain a valuation allowance until sufficient positive evidence exists to support its reversal.
The valuation allowance for deferred tax assets was:

	As of June 30		2014					2013					2012
	Balance at beginning of period			$	27,753				$	36,763				$	30,618
	Change in valuation allowance				5,139					2,059					6,145
	Permanent adjustment for Other Comprehensive Income				—					(2,016	)				—
	OGR acquisition adjustments				—					(9,053	)				—
	Balance at end of period			$	32,892				$	27,753				$	36,763


The valuation allowance for deferred tax assets as of June 30, 2014, includes $27,355 related to domestic jurisdictions and $5,537 related to foreign jurisdictions.
The change in valuation allowance for the year ended June 30, 2013, included a reversal of $9,053 of valuation allowance previously established against the Company’s deferred tax assets in the United States. The reversal was required to offset deferred tax liabilities established as part of the OGR acquisition related to acquired amortizable intangible assets.
The Company has domestic federal net operating loss carry forwards of approximately $43,872 that expire in 2027 through 2034, state net operating loss carry forwards of approximately $73,939 that expire over various periods beginning in 2014 and foreign net operating loss carry forwards of approximately $26,456 that expire over various periods beginning in 2014.
A reconciliation of the beginning and ending amount of unrecognized tax benefits (“UTB”) is as follows:

	As of June 30		2014					2013					2012
	Unrecognized tax benefits at beginning of			$	12,261				$	6,565				$	6,180
	period			$	12,261				$	6,565				$	6,180
	Additions based on tax positions related to prior periods				1,276					4,996					216
	Additions based on tax positions related to the current period				1,036					404					646
	Reductions related to settlements with tax authorities				(2,215	)				—					—
	Reductions due to lapse of statute of limitations				(5,157	)				—					—
	Exchange effect				219					296					(477	)
	Unrecognized tax benefits at end of period			$	7,420				$	12,261				$	6,565


The entire liability for UTB relates to unrecognized tax positions that, if recognized, would affect the annual effective tax rate. The entire amount of the liability for UTB is classified as a long-term liability, except for $1,218 that is classified as a current liability at June 30, 2014. We believe it is reasonably possible that a portion of the UTB may be recognized during 2015 as a result of the lapse of the statute of limitations.
We recognize interest and penalties associated with uncertain tax positions as a component of the provision for income taxes. We recognized interest and penalties in the consolidated statements of operations of $(661), $441 and $307 for 2014, 2013 and 2012, respectively. Accrued interest and penalties included in the consolidated balance sheets were $1,344 and $1,952 at June 30, 2014 and June 30, 2013, respectively.
Our Israel subsidiaries have been under examination for fiscal years 2009 through 2012. In April 2014, certain of these subsidiaries reached a settlement to pay additional income taxes totaling $2,614. As a result of the settlement, we recorded a reduction to our income tax provision of $572 and a reduction in previously unrecognized tax benefits of $2,215. We expect the remaining open examinations to conclude within the next twelve months, the effect of which is not expected to be significant to our consolidated financial statements. We have no open examinations that we believe would result in a material change to our liability for uncertain tax positions.
We file income tax returns in the U.S. federal and various U.S. state and international jurisdictions. Our U.S. federal and material U.S. state income tax returns have been closed for periods through June 30, 2006. Income tax returns for our significant foreign subsidiaries are closed through the following periods:
•
In Brazil, through December 31, 2008
•
In Israel, through June 30, 2009 or June 30, 2012

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	13
	Commitments and Contingencies
	Leases
	We lease land and office, warehouse and manufacturing equipment and facilities for minimum annual rentals, plus certain cost escalations. We record rent expense on a straight line basis over the term of the lease. At June 30, 2014, we had the following future minimum lease commitments:

		For the Years Ended June 30	Capital				Non-cancellable
		For the Years Ended June 30	leases				operating leases
		2015		$	81			$	4,486
		2016			21				4,033
		2017			8				3,696
		2018			—				3,059
		2019			—				2,641
		Thereafter			—				4,668
		Total minimum lease payments		$	110			$	22,583
		Amounts representing interest			(16	)
		Present value of minimum lease payments		$	94


	Rent expense under operating leases was $6,958, $6,084, and $6,085 for 2014, 2013 and 2012, respectively.
	Environmental
	Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are generally included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.
	While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.
	The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
	We, our subsidiary C.P. Chemicals, Inc. (“CP”) and other defendants reached a phased settlement with Chevron U.S.A. Inc. (“Chevron”), and a Settlement Agreement and Consent Order (the “Consent Order”) was filed and entered by the United States District Court for the District of New Jersey (the “Court”), resolving a 1997 complaint filed by Chevron. The complaint alleged that the operations of CP at its Sewaren, New Jersey plant affected adjoining property owned by Chevron and we were also responsible to Chevron. Pursuant to the Consent Order, CP, the Company and co-defendant Legacy Vulcan Corp. (“Vulcan”), through an entity known as North Field Extension, LLC (“NFE”), acquired a portion of the Chevron property. NFE will proceed with any required investigation and remediation of the acquired property and also assumed responsibility for certain types of environmental conditions (if they exist) on the portion of the property retained by Chevron. We (together with CP) and Vulcan will each be responsible for 50% of the investigation and remediation costs, which are to be paid by us directly or through NFE. We believe that insurance recoveries will be available to offset some of those costs. Another defendant also made a $175 contribution toward the remediation costs to be incurred by NFE. Chevron retained responsibility for further investigation and remediation of certain identified environmental conditions on the portion of the property retained by it, as well as in one area of the property acquired by NFE.
	The EPA is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of Phibro-Tech’s Santa Fe Springs, California facility. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that groundwater contamination at its site is due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a nearby property owner has filed a complaint in the Superior Court of the State of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for alleged contamination of groundwater underneath its property; a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site; and that same group of companies has served Phibro-Tech with a Notice of Endangerment and Intent to Sue Pursuant to RCRA § 7002(a)(1)(B) seeking to abate alleged imminent and substantial endangerment to health or the environment resulting from the lack of adequate offsite monitoring and groundwater source control associated with former and/or continuing operations at Phibro-Tech’s Santa Fe Springs facility. Due to the ongoing nature of the EPA’s investigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.
	Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for complying with the NFE Consent Order and for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be approximately $7,273 and $8,292 at June 30, 2014 and 2013, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.
	Claims and Litigation
	During the quarter ended June 30, 2014, we recognized a $5,350 loss in our consolidated statement of operations on the insurance claim previously recorded as an asset. In 2010, certain customers claimed damages to their poultry resulting from the use of one of our animal health products. We believed we were entitled to coverage for the claimed damages under our insurance policies, above any applicable self-insured retention or deductible. Our insurance carrier refused to cover the damages claimed and denied coverage. We instituted a legal action to enforce our rights under the policies but in June 2014 the trial court ruled against us. We have appealed the trial court’s decision. In July 2014, we reached settlements with and made payments to our customers for their claims in amounts approximately equal to the liability previously accrued.
	PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
	Employment and Severance Agreements
	We have entered into employment agreements with certain executive management and other employees which specify severance benefits of up to 15 months of the employee’s compensation.

Derivatives

12 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives

We monitor our exposure to commodity prices, interest rates and foreign currency exchange rates, and use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). We record the portion of the changes in the expected cash flows related to a recognized asset or liability (the effective portion) in accumulated other comprehensive income (loss). As the hedged item is realized, we report the gain or loss included in accumulated other comprehensive income (loss) in the consolidated statements of operations on the same line as the hedged item. We immediately recognize in the consolidated statements of operations in the same line as the hedged item, the portion of the changes in fair value of derivatives used as cash flow hedges that is not offset by changes in the expected cash flows related to a recognized asset or liability (the ineffective portion).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting, and recognize in the consolidated statements of operations, in the period the derivative no longer qualifies as a hedge, any gains or losses on the derivative.

We record derivatives at fair value in prepaid expenses and other current assets in the consolidated balance sheets. We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments (level 2 inputs per ASC 820).

At June 30, 2014, significant outstanding derivatives employed to manage market risk and designated as cash flow hedges were:

Instrument

Hedge

Notional

Fair value as of June 30,

amount at

June 30, 2014

2014

2013

Options

Brazilian Real calls

R$ 78,000

432

365

Options

Brazilian Real puts

(R$ 78,000)

(46

)

(1,004

)

The unrecognized gains (losses) at June 30, 2014, are unrealized and will change depending on future exchange rates until the underlying contracts mature. Of the $386 of unrecognized gains (losses) on derivative instruments included in accumulated other comprehensive income (loss) at June 30, 2014, we anticipate $386 of the current fair value would be recorded in earnings within the next twelve months. We recognize gains (losses) on derivative instruments as a component of cost of goods sold when the hedged item is sold. We hedge forecasted transactions for periods not exceeding the next twenty-four months.

Fair_Value_Measurements

Fair Value Measurements

12 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

In assessing the fair value of financial instruments at June 30, 2014 and 2013, we used a variety of methods and assumptions which were based on estimates of market conditions and risks existing at the time.

Current Assets and Liabilities

We consider the carrying amounts of current assets and current liabilities, except the current portion of long-term debt, to be representative of their fair value because of the current nature of these items.

Letters of Credit

We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The contract values of the letters of credit at June 30, 2014 and 2013, were $17,140 and $14,954 respectively. The carrying values of these letters of credit are considered to be representative of their fair values because of the nature of the instruments.

Long Term Debt

We estimated the fair value of the Term B Loan and the Senior Notes based on quoted broker prices (level 2 inputs per ASC 820) and the fair values of the term loans based on quoted yields for the Senior Notes which were similar in structure, maturity and interest rate (level 2 inputs per ASC 820).

As of June 30

2014

2013

Fair values

Term B Loan

289,638

—

Senior notes due July 1, 2018

—

322,500

Term loan payable to Mayflower due December 31, 2016

—

26,968

Term loan payable to BFI due August 1, 2014

—

10,644

Business_Segments

Business Segments	12 Months Ended
Business Segments	Jun. 30, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	16
	Business Segments
	The Animal Health segment manufactures and markets products for the poultry, swine, cattle, dairy, aquaculture and ethanol markets. The business includes net sales of medicated feed additives and other related products, nutritional specialty products and vaccines. The Mineral Nutrition segment manufactures and markets trace minerals for the cattle, swine, poultry and pet food markets. The Performance Products segment manufactures and markets a variety of products for use in the personal care, automotive, industrial chemical and chemical catalyst industries.
	We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments. We do not allocate such items to the principal segments because they are not used to evaluate their operating results or financial position. Corporate costs include the departmental operating costs of the Board of Directors, the Chairman, President and Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer, the Senior Vice President and General Counsel, the Senior Vice President of Human Resources, the Chief Information Officer and the Executive Vice President of Corporate Strategy. Costs include the executives and their staffs and include compensation and benefits, outside services, professional fees and office space. Assets include cash and cash equivalents, debt issue costs and certain other assets.
	We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual or non-recurring. We define EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization.
	The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.
		For the Years Ended June 30	2014				2013				2012
		Net sales
		Animal Health		$	431,053			$	384,941			$	375,167
		Mineral Nutrition			201,599				203,169				210,091
		Performance Products			59,262				65,041				68,843
				$	691,914			$	653,151			$	654,101
		Adjusted EBITDA
		Animal Health		$	100,280			$	82,997			$	70,456
		Mineral Nutrition			11,636				12,069				13,007
		Performance Products			4,626				2,927				5,132
		Corporate			(25,945	)			(22,239	)			(21,743	)
				$	90,597			$	75,754			$	66,852
		Reconciliation of Adjusted EBITDA to income before income taxes
		Adjusted EBITDA		$	90,597			$	75,754			$	66,852
		Depreciation and amortization			(21,453	)			(19,023	)			(17,527	)
		Loss on insurance claim			(5,350	)			—				—
		Interest expense, net			(32,962	)			(35,629	)			(35,419	)
		Foreign currency gains (losses), net			(1,753	)			(3,103	)			(1,192	)
		Loss on extinguishment of debt			(22,771	)			—				—
		Other income (expense), net			—				(151	)			400
		Income before income taxes		$	6,308			$	17,848			$	13,114


		As of June 30	2014				2013
		Identifiable assets
		Animal Health		$	361,376			$	329,323
		Mineral Nutrition			57,460				64,719
		Performance Products			23,429				21,233
		Corporate			30,058				58,867
				$	472,323			$	474,142

	The Animal Health segment includes all goodwill. The Animal Health segment includes advances to and investment in equity method investee of $5,140 and $4,734 as of June 30, 2014 and 2013, respectively. The Performance Products segment includes an investment in equity method investee of $479 and $275 as of June 30, 2014 and 2013, respectively. Corporate includes all cash and cash equivalents.
	During our fiscal quarter ended December 31, 2013, we reorganized our reportable segments for financial reporting to better align them with how we currently review operating results for purposes of allocating resources and managing performance. We created two new reportable segments, the Animal Health segment and the Mineral Nutrition segment, and eliminated the Animal Health & Nutrition (AH&N) segment. The Animal Heath segment consists of the business units within the former AH&N segment, excluding the Mineral Nutrition business unit, which is now a separate reportable segment. In accordance with ASC 280, Segment Reporting, we have reclassified all amounts to conform to our new reportable segment presentation.

Geographic_Information

Geographic Information	12 Months Ended
Geographic Information	Jun. 30, 2014
Segments, Geographical Areas [Abstract]	'
Geographic Information	'
	17
	Geographic Information
	The following is information about our geographic operations. Information is attributed to the geographic areas based on the locations of our subsidiaries.

		For the Years Ended June 30	2014			2013			2012
		Net sales
		United States		$	435,414		$	414,768		$	424,373
		Israel			89,739			93,248			101,301
		Latin America and Canada			84,775			68,575			61,407
		Europe and Africa			38,563			32,501			30,087
		Asia/Pacific			43,423			44,059			36,933
				$	691,914		$	653,151		$	654,101



		As of June 30	2014			2013
		Property, plant and equipment, net
		United States		$	40,926		$	40,601
		Israel			33,426			30,837
		Brazil			32,946			30,988
		Other			1,861			1,996
				$	109,159		$	104,422

Selected_Quarterly_Results_of_

Selected Quarterly Results of Operations Data (Unaudited)	12 Months Ended
Selected Quarterly Results of Operations Data (Unaudited)	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Results of Operations Data (Unaudited)	'
	18. Selected Quarterly Results of Operations Data (Unaudited)
	The quarterly consolidated statement of operations information was prepared on the same basis as, and should be read in conjunction with, the audited consolidated financial statements and related notes included herein.
			Quarters																	Year
			Quarters																	Year
		For the Periods Ended		September 30,				December 31,				March 31,				June 30,					June 30,
		For the Periods Ended		2013				2013				2014				2014					2014
				(in thousands)
		Net sales
		Animal Health			$	101,171			$	107,966			$	107,808			$	114,108				$	431,053
		Mineral Nutrition				46,186				50,633				49,901				54,879					201,599
		Performance Products				14,871				14,143				15,558				14,690					59,262
		Total net sales				162,228				172,742				173,267				183,677					691,914
		Cost of goods sold				112,716				121,586				120,425				129,412					484,139
		Gross profit				49,512				51,156				52,842				54,265					207,775
		Selling, general and administrative expenses				33,115				34,138				35,520				41,208					143,981
		Operating income (loss)				16,397				17,018				17,322				13,057					63,794
		Interest expense				8,779				8,787				8,810				6,705					33,081
		Interest (income)				(44	)			(68	)			(66	)			59					(119	)
		Foreign currency (gains) losses, net				648				1,165				275				(335	)				1,753
		Loss on extinguishment of debt				—				—				—				22,771					22,771
		Income (loss) before income taxes				7,014				7,134				8,303				(16,143	)				6,308
		Provision (benefit) for income taxes				1,171				4,832				1,933				1,499					9,435
		Net income (loss)			$	5,843			$	2,302			$	6,370			$	(17,642	)			$	(3,127	)
		Net income per share−basic and diluted			$	0.19			$	0.08			$	0.21			$	(0.47	)			$	(0.10	)
		Adjusted EBITDA
		Animal Health			$	24,107			$	24,522			$	25,505			$	26,146				$	100,280
		Mineral Nutrition				2,460				2,878				2,807				3,491					11,636
		Performance Products				1,096				1,103				906				1,521					4,626
		Corporate				(6,065	)			(6,193	)			(6,774	)			(6,913	)				(25,945	)
		Adjusted EBITDA			$	21,598			$	22,310			$	22,444			$	24,245				$	90,597



				Quarters																	Year
		For the Periods Ended		September 30,				December 31,				March 31,				June 30,					June 30,
		For the Periods Ended		2012				2012				2013				2013					2013
				(in thousands)
		Net sales
		Animal Health			$	96,128			$	94,236			$	93,883			$	100,694				$	384,941
		Mineral Nutrition				49,792				52,892				51,757				48,728					203,169
		Performance Products				16,186				17,031				17,045				14,779					65,041
		Total net sales				162,106				164,159				162,685				164,201					653,151
		Cost of goods sold				120,240				120,973				116,929				116,045					474,187
		Gross profit				41,866				43,186				45,756				48,156					178,964
		Selling, general and administrative expenses				28,657				29,030				31,295				33,251					122,233
		Operating income (loss)				13,209				14,156				14,461				14,905					56,731
		Interest expense				8,893				8,969				8,901				9,008					35,771
		Interest (income)				(68	)			(14	)			(26	)			(34	)				(142	)
		Foreign currency (gains) losses, net				168				126				838				1,971					3,103
		Other (income) expense, net				(12	)			58				482				(377	)				151
		Income (loss) before income taxes				4,228				5,017				4,266				4,337					17,848
		Provision (benefit) for income taxes				1,569				(7,056	)			86				(1,642	)				(7,043	)
		Net income (loss)			$	2,659			$	12,073			$	4,180			$	5,979				$	24,891
		Net income per share−basic and diluted			$	0.09			$	0.4			$	0.14			$	0.2				$	0.82
		Adjusted EBITDA
		Animal Health			$	20,103			$	19,516			$	20,334			$	23,044				$	82,997
		Mineral Nutrition				2,690				3,175				3,439				2,765					12,069
		Performance Products				1,145				1,826				1,577				(1,621	)				2,927
		Corporate				(6,033	)			(5,739	)			(5,930	)			(4,537	)				(22,239	)
		Adjusted EBITDA			$	17,905			$	18,778			$	19,420			$	19,651				$	75,754

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and New Accounting Standards (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation and Basis of Presentation	'
	Principles of Consolidation and Basis of Presentation
	The consolidated financial statements include the accounts of Phibro and all majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.
	We present our financial statements on the basis of our fiscal year ending June 30. All references to years in these consolidated financial statements refer to the fiscal year ending or ended on June 30 of that year.
	Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
	During the year ended June 30, 2014, we identified and corrected an error in prior period cash flows related to an equity method investment. We corrected the error and increased cash flows from operating activities and decreased cash flows from investing activities by $1,022 and $106 for 2013 and 2012, respectively. The error had no impact to the consolidated statements of operations, consolidated comprehensive income or the consolidated balance sheet. We have assessed the effects of the correction and have concluded the items were not material to our prior period consolidated financial statements. Accordingly we have revised the prior year statements of consolidated cash flows.
	During the quarter ended December 31, 2013, we identified and corrected errors that originated in prior periods. The error corrections increased income before income taxes by $358 in the current year. We have assessed the effects of the corrections and have concluded the items were not material, either individually or in aggregate, to our current year results of operations or any other prior period consolidated financial statements.
Risks, Uncertainties and Liquidity	'
	Risks, Uncertainties and Liquidity
	An expansion of the regulatory restrictions on the use of antibiotics or antibacterials in food-producing animals could result in a decrease in our sales. The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on or banning of the use of antibiotics in food-producing animals. The sale of antibiotics and antibacterials is a material portion of our business. Should regulatory or other developments result in restrictions on the sale of such products, it could have a material adverse effect on our financial position, results of operations and cash flows.
	The testing, manufacturing, and marketing of certain of our products are subject to extensive regulation by numerous government authorities in the United States and other countries.
	We have significant assets in Israel, Brazil and other locations outside of the United States and a significant portion of our sales and earnings are attributable to operations conducted abroad. Our assets, results of operations and future prospects are subject to currency exchange fluctuations and restrictions, energy shortages, other economic developments, political or social instability in some countries, and uncertainty of, and governmental control over, commercial rights, which could result in a material adverse effect on our financial position, results of operations and cash flows.
	We are subject to environmental laws and regulations governing the use, storage, handling, generation, treatment, emission, release, discharge and disposal of certain materials and wastes, the remediation of contaminated soil and groundwater, the manufacture, sale and use of regulated materials, including pesticides, and the health and safety of employees. As such, the nature of our current and former operations and those of our subsidiaries expose Phibro and our subsidiaries to the risk of claims with respect to such matters.
Use of Estimates	'
	Use of Estimates
	Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Actual results could differ from these estimates. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill, realizability of deferred income tax and value-added tax assets, legal and environmental matters and actuarial assumptions related to our pension plans. We regularly evaluate our estimates and assumptions using historical experience and other factors. Our estimates are based on complex judgments, probabilities and assumptions that we believe to be reasonable.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue upon transfer of title and when risk of loss passes to the customer. Certain of our businesses have terms of FOB shipping point where title and risk of loss transfer on shipment. Certain of our businesses have terms of FOB destination where title and risk of loss transfer on delivery. In the case of FOB destination, revenue is not recognized until products are received by the customer. Additional conditions for recognition of revenue are that persuasive evidence of an arrangement exists, the selling price is fixed or determinable, collections of sales proceeds are reasonably assured and we have no further performance obligations. We record estimated reductions to revenue for customer programs and incentive offerings, including pricing arrangements and other volume-based incentives, at the time the sale is recorded. Royalty and licensing income from licensing agreements are recognized when earned under the terms of the related agreements and are included in Net Sales in the consolidated statements of operations. Net Sales also include shipping and handling fees billed to customers. Delivery costs to our customers are included in cost of goods sold in the consolidated statements of operations.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash equivalents include highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. We believe we mitigate such risk by investing in or through major financial institutions.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are recorded at the invoiced amount and do not bear interest. We grant credit terms in the normal course of business and do not normally require collateral or other security to support credit sales. Our ten largest customers represented, in the aggregate, approximately 21% and 24% of accounts receivable at June 30, 2014 and 2013, respectively.
	The allowance for doubtful accounts is our best estimate of the probable credit losses in existing accounts receivable. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We also monitor domestic and international economic conditions for the potential effect on our customers. Past due balances are reviewed individually for collectability. Bad debts have been minimal. Account balances are charged against the allowance when we determine it is probable the receivable will not be recovered.
Inventories	'
	Inventories
	Inventories are valued at the lower of cost or market. Cost is determined principally under weighted average and standard cost methods, which approximate first-in, first-out (FIFO) cost. Obsolete and unsalable inventories, if any, are reflected at estimated net realizable value. Inventory costs include materials, direct labor and manufacturing overhead.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost. We capitalize interest expense as part of the cost of construction of facilities and equipment. No interest expense was capitalized in 2014, 2013 and 2012.
	Depreciation is charged to results of operations using the straight-line method based upon the assets’ estimated useful lives ranging from 8 to 25 years for buildings and improvements and 3 to 16 years for machinery and equipment.
	We capitalize costs that extend the useful life or productive capacity of an asset. Repair and maintenance costs are expensed as incurred. In the case of disposals, the assets and related accumulated depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in the consolidated statements of operations.
Capitalized Software Costs	'
	Capitalized Software Costs
	We capitalize costs to obtain, develop and implement software for internal use in accordance with FASB Accounting Standards Codification (“ASC”) 350-40, Internal Use Software. Amounts paid to third parties and costs of internal employees who are directly associated with the software project are also capitalized, depending on the stage of development. We expense software costs that do not meet the capitalization criteria. Capitalized software costs are included in property, plant and equipment on the consolidated balance sheets and are amortized on a straight-line basis over seven years.
Deferred Financing Costs	'
	Deferred Financing Costs
	Costs and original issue discounts or premiums related to issuance or modification of our debt are deferred on the consolidated balance sheet and amortized over the lives of the respective debt instruments. Amortization of deferred financing costs is included in interest expense in the consolidated statements of operations.
Acquisitions, Intangible Assets and Goodwill	'
	Acquisitions, Intangible Assets and Goodwill
	Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition, with any excess of the purchase price over the fair values of the net assets acquired recorded as goodwill.
	Significant judgment is required to determine the fair value of certain tangible and intangible assets and in assigning their respective useful lives. Accordingly, we typically obtain the assistance of third-party valuation specialists for significant tangible and intangible assets. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We typically use an income method to measure the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product or technology life cycles, economic barriers to entry and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets are primarily based on a number of factors including competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations.
Long-Lived Assets and Goodwill	'
	Long-Lived Assets and Goodwill
	We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. An impairment loss would be recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded is calculated by the excess of the asset’s carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations. We have not experienced significant changes in the carrying value or estimated remaining useful lives of our long-lived or amortizable intangible assets in the periods included in the consolidated financial statements.
	We annually evaluate goodwill for impairment by comparing the book value to the fair value of the reporting unit to which the goodwill relates. If circumstances change significantly, we would also test a reporting unit’s goodwill for impairment during interim periods between its annual tests. We determine the fair value of the reporting units using a discounted cash flow analysis method. Considerable management judgment, such as assumptions of forecasted growth rates and discount rate, is necessary in arriving at the fair value. Application of alternative assumptions, such as changes in the estimate of future cash flows, could produce significantly different results. Because of the significance of the judgments and estimation processes, it is likely that different amounts could be recorded if we used different assumptions or if the underlying circumstances were to change. During the quarter ended June 30, 2014, we performed the annual goodwill impairment test and determined that none of the goodwill was impaired.
Foreign Currency Translation	'
	Foreign Currency Translation
	We generally use local currency as the functional currency to measure the financial position and results of operations of each of our international subsidiaries. We translate assets and liabilities of these operations at the exchange rates in effect at the balance sheet date. We translate income statement accounts at the average rates of exchange prevailing during the period. Translation adjustments that arise from the use of differing exchange rates from period to period are included in accumulated other comprehensive income (loss) in stockholders’ equity (deficit).
	Certain of our Israeli operations have designated the U.S. dollar as their functional currency. Gains and losses arising from remeasurement of local currency accounts into U.S. dollars are included in determining net income or loss.
	Foreign currency gains and losses primarily arise from intercompany balances.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) consists of net income (loss) and the changes in: (i) the fair value of derivative instruments; (ii) foreign currency translation adjustment; (iii) unrecognized net pension gains (losses); and (iv) the related (provision) benefit for income taxes.
Derivative Financial Instruments	'
	Derivative Financial Instruments
	We record all derivative financial instruments on the consolidated balance sheets at fair value. Changes in the fair value of derivatives are recorded in results of operations or accumulated other comprehensive income (loss), depending on whether a derivative is designated and effective as part of a hedge transaction and, if so, the type of hedge transaction. Gains and losses on derivative instruments reported in accumulated other comprehensive income (loss) are included in the results of operations in the periods in which operations are affected by the hedged item.
	From time to time, we use forward contracts and options to mitigate exposure to changes in foreign currency exchange rates and as a means of hedging forecasted operating costs. To qualify a derivative as a hedge, we document the nature and relationships between hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. We hedge forecasted transactions for periods not exceeding the next twenty-four months. We do not engage in trading or other speculative uses of financial instruments.
Fair Value Measurements	'
	Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. ASC 820 uses a three level hierarchy to prioritize the inputs used in measuring fair value. Level 1 inputs include quoted prices in active markets for identical assets or liabilities. Level 2 inputs include observable inputs other than level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Environmental Liabilities	'
	Environmental Liabilities
	Expenditures for ongoing compliance with environmental regulations are expensed or capitalized as appropriate. We capitalize expenditures made to extend the useful life or productive capacity of an asset, including expenditures that prevent future environmental contamination. Other expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. We record the expense and related liability in the period an environmental assessment indicates remedial efforts are probable and the costs can be reasonably estimated. Estimates of the liability are based upon currently available facts, existing technology and presently enacted laws and regulations taking into consideration the likely effects of inflation and other societal and economic factors. All available evidence is considered, including prior experience in remediation of contaminated sites, other companies’ experiences and data released by the U.S. Environmental Protection Agency or other organizations. The estimated liabilities are not discounted. We record anticipated recoveries under existing insurance contracts if probable.
Income Taxes	'
	Income Taxes
	The provision for income taxes includes U.S. federal, state, and foreign income taxes. Our annual tax rate is determined based on our income, statutory tax rates, the tax effects of items treated differently for tax purposes than for financial reporting purposes and tax planning opportunities available in the various jurisdictions in which we operate. Tax law requires certain items be included in the tax return at different times than the items are reflected in the consolidated financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences create deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our consolidated statements of operations. Deferred tax liabilities generally represent tax expense recognized in our consolidated financial statements for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our consolidated financial statements and assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment.
	Significant judgment is required in determining our tax provision and in evaluating our tax positions. The recognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, primarily net operating loss carryforwards, is dependent upon generating sufficient taxable income in the appropriate jurisdiction prior to the expiration of the carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.
	We operate in multiple jurisdictions with complex tax policy and regulatory environments. In certain of these jurisdictions, we may take tax positions that management believes are supportable, but are potentially subject to successful challenge by the applicable taxing authority. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly.
	Because there are a number of estimates and assumptions inherent in calculating the various components of our tax provision, future events such as changes in tax legislation, the geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an effect on those estimates and our effective tax rate.
Research and Development Expenditures	'
	Research and Development Expenditures
	Research and development expenditures are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Most of our manufacturing facilities have chemists and technicians on staff involved in product development, quality assurance, quality control and also providing technical services to customers. Research, development and technical service efforts are conducted at various facilities. We operate animal health research and development facilities in Guarulhos, Brazil; Beit Shemesh, Israel; Naot Hovav, Israel; Quincy, Illinois; St. Paul, Minnesota; Corvallis, Oregon; and Manhattan, Kansas. These facilities provide research and development services relating to: fermentation development and micro-biological strain improvement; vaccine development; chemical synthesis and formulation development; nutritional supplement development; and ethanol-related products.
Stock-Based Compensation	'
	Stock-Based Compensation
	All stock-based compensation to employees, including grants of stock options, is expensed over the requisite service period based on the grant date fair value of the awards. We determine the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options.
Net Income per Share and Weighted Average Shares	'
	Net Income per Share and Weighted Average Shares
	Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.
	Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares resulting from the exercise of stock options and warrants. For the year ended June 30, 2014, there was a net loss; and we excluded 296,162 net shares of stock options and warrants from the calculation of diluted net income (loss) per share because of the anti-dilutive effect from the assumed exercise of these options and warrants. For the years ended June 30, 2013 and 2012, the stock options and warrants had an exercise price greater than the estimated market value and were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options and warrants was anti-dilutive.
New Accounting Standards	'
	New Accounting Standards
	We have elected to adopt new accounting standards within the specified effective date established for public companies, where applicable.
	Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, clarifies when it is appropriate for an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset. ASU 2013-11 was effective for interim and annual periods beginning after December 15, 2013. Early adoption is permitted. The guidance should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however, retrospective application is also permitted. We elected to early adopt the provisions of this pronouncement, and it did not have a material effect on our consolidated financial statements.
	ASU 2014-08, Presentation of Financials (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, changes the criteria for reporting a discontinued operation while enhancing disclosures. Under the new guidance, a disposal of a component of an entity or group of components of an entity that represents a strategic shift that has, or will have, a major effect on operations and financial results is a discontinued operation when any of the following occurs: (i) it meets the criteria to be classified as held for sale, (ii) it is disposed of by sale, or (iii) it is disposed of other than by sale. Also, a business that, on acquisition, meets the criteria to be classified as held for sale is reported in discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations, as well as disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation. The guidance is effective prospectively for all disposals (or classifications as held for sale) of components of an entity and all businesses that, on acquisition, are classified as held for sale, that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
	ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2016. Early adoption is not permitted. The guidance should be applied retrospectively to each prior reporting period presented. We are currently evaluating the impact that adopting this guidance will have on our consolidated financial statements.
	ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Management will need to assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will need to consider relevant conditions that are known and reasonably knowable at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Under the new standard, the definition of substantial doubt incorporates a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies. ASU 2014-15 will be effective for annual periods ending after December 15, 2016. Earlier adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.

Initial_Public_Offering_and_Re1

Initial Public Offering and Refinancing (Tables)	12 Months Ended
Initial Public Offering and Refinancing (Tables)	Jun. 30, 2014
Initial Public Offering And Refinancing [Abstract]	'
Schedule of the summary of loss on early extinguishment of debt	'
		Redemption premium on Senior Notes	$	17,184
		Write-off of original issue discount related to Senior Notes and BFI term loan		2,123
		Write-off of capitalized debt issuance costs related to Senior Notes, Mayflower term loan, BFI term loan and cancelled domestic senior credit facility and other items		3,464
		Loss on extinguishment of debt	$	22,771

Statements_of_OperationsAdditi1

Statements of Operations-Additional Information (Tables)	12 Months Ended
Statements of Operations-Additional Information (Tables)	Jun. 30, 2014
Supplemental Income Statement Elements [Abstract]	'
Schedule of additional information of statements of operations	'
		For the Years Ended June 30	2014			2013			2012
		Depreciation and amortization
		Depreciation of property, plant and equipment		$	16,439		$	14,917		$	14,425
		Amortization of intangible assets			4,897			4,106			3,048
		Amortization of other assets			117			—			54
		Depreciation and amortization		$	21,453		$	19,023		$	17,527



		Research and development expenditures		$	8,212		$	6,638		$	7,189

Balance_SheetsAdditional_Infor1

Balance Sheets-Additional Information (Tables)	12 Months Ended
Balance Sheets-Additional Information (Tables)	Jun. 30, 2014
Balance Sheets Additional Information [Abstract]	'
Schedule of additional information of balance sheets	'
		As of June 30		2014					2013
		Accounts receivable, net
		Trade accounts receivable			$	115,093				$	99,795
		Allowance for doubtful accounts				(1,235	)				(658	)
					$	113,858				$	99,137
		Allowance for doubtful accounts(1)
		Balance at beginning of period			$	658				$	1,041
		Provision for bad debts				226					(124	)
		Effect of changes in exchange rates				351					(265	)
		Bad debt write-offs (recovery)				—					6
		Balance at end of period			$	1,235				$	658



	-1
	For the year ended June 30, 2012, the beginning balance for allowance for doubtful accounts was $1,029, the provision for bad debts was ($115) and the effect of changes in exchange rates was $127, resulting in an ending balance for allowance for doubtful accounts of $1,041.

		As of June 30		2014					2013
		Inventories, net
		Raw materials			$	44,306				$	36,589
		Work-in-process				7,518					7,541
		Finished goods				91,360					95,902
					$	143,184				$	140,032
		Property, plant and equipment, net
		Land			$	9,773				$	9,746
		Buildings and improvements				51,364					46,960
		Machinery and equipment				172,530					156,247
						233,667					212,953
		Accumulated depreciation				(124,508	)				(108,531	)
					$	109,159				$	104,422



		As of June 30		Weighted-					2014				2013
				Average
				Useful Life
				(Years)
		Intangibles, net
		Cost
		Medicated feed additive product registrations				10				$	11,792			$	12,115
		Rights to sell in international markets				10					4,292				4,292
		Customer relationships				13					10,702				10,691
		Technology				11					28,259				28,259
		Distribution agreements				4					3,447				3,493
		Trade names, trademarks and other				5					2,740				2,740
											61,232				61,590
		Accumulated amortization
		Medicated feed additive product registrations									(11,039	)			(10,778	)
		Rights to sell in international markets									(4,292	)			(3,861	)
		Customer relationships									(4,265	)			(3,203	)
		Technology									(6,510	)			(3,729	)
		Distribution agreements									(3,309	)			(3,179	)
		Trade names, trademarks and other									(2,014	)			(1,685	)
											(31,429	)			(26,435	)
										$	29,803			$	35,155



		As of June 30		2014					2013
		Other assets
		Goodwill			$	12,613				$	12,613
		Advances to and investments in equity method investees				5,619					3,515
		Insurance investments				4,626					4,456
	Deferred financing fees				5,199					5,212
	Deferred income taxes				3,486					4,755
	Insurance claim receivable				—					5,350
	Other				2,529					2,278
				$	34,072				$	38,179


	As of June 30		2014					2013
	Goodwill roll-forward
	Balance at beginning of period			$	12,613				$	1,717
	OGR acquisition				—					10,896
	Balance at end of period			$	12,613				$	12,613
	Accrued expenses and other current liabilities
	Employee related accruals			$	20,813				$	17,823
	Interest				—					13,875
	Commissions and rebates				2,973					3,196
	Insurance related				1,395					1,286
	Professional fees				4,229					4,064
	Deferred consideration on acquisitions				1,420					1,250
	Product liability claims				5,286					—
	Other accrued liabilities				13,745					15,944
				$	49,861				$	57,438
	Other liabilities
	Pension and other retirement benefits			$	31,025				$	26,021
	Long term and deferred income taxes				14,282					17,580
	Deferred consideration on acquisitions				2,879					5,009
	Product liability claims				—					5,600
	Other long term liabilities				10,128					7,926
				$	58,314				$	62,136



	As of June 30		2014					2013
	Accumulated other comprehensive income (loss)
	Derivative instruments			$	386				$	(639	)
	Foreign currency translation adjustment				(1,409	)				(2,519	)
	Unrecognized net pension gains (losses)				(16,663	)				(12,240	)
	Income tax (provision) benefit on derivative instruments				63					63
	Income tax (provision) benefit on pension gains (losses)				(2,437	)				(2,437	)
				$	(20,060	)			$	(17,772	)

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
Acquisition (Tables)	Jun. 30, 2014
Business Combinations [Abstract]	'
Schedule of allocation of the purchase price after valuation adjustments	'

		Assets
		Property, plant and equipment		$	1,202
		Intangibles			23,781
		Goodwill			10,896
		Total assets		$	35,879
		Liabilities
		Other current and long-term liabilities		$	13,129
		Total liabilities			13,129
		Net assets acquired		$	22,750

Schedule of unaudited pro forma consolidated results of operations	'

		For the Years Ended June 30	2013			2012
		Net sales		$	653,151		$	654,101
		Net income (loss)			25,989			9,170
		Net income (loss) per share−basic and diluted			0.85			0.3
		Adjusted EBITDA			77,731			70,804

Debt_Tables

Debt (Tables)	12 Months Ended
Debt (Tables)	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of long term debt	'

		As of June 30	2014				2013
		Term B loan due April 15, 2021		$	290,000			$	—
		Senior notes due July 1, 2018			—				300,000
		Term loan payable to Mayflower due December 31, 2016			—				24,000
		Term loan payable to BFI due August 1, 2014			—				10,000
		Capitalized lease obligations			94				132
					290,094				334,132
		Unamortized debt discount			(703	)			(2,528	)
					289,391				331,604
		Less: current maturities			(2,969	)			(64	)
				$	286,422			$	331,540

Schedule of aggregate maturities of long term debt	'

		For the Years Ended June 30
		2015	$ 2,969
		2016	2,918
		2017	2,907
		2018	2,900
		2019	2,900
		Thereafter	275,500
		Total	$290,094

Preferred_and_Common_Shares_Ta

Preferred and Common Shares (Tables)	12 Months Ended
Preferred and Common Shares (Tables)	Jun. 30, 2014
Equity [Abstract]	'
Schedule of preferred shares and common shares	'
			2014		2013					2014		2013
		As of June 30	Authorized shares				Par value			Issued and outstanding shares
		Preferred stock		16,000,000		—		$	0.0001		—		—
		Common stock−Class A		300,000,000		—		$	0.0001		17,442,953		—
		Common stock−Class B		30,000,000		—		$	0.0001		21,348,600		—
		Preferred stock		—		1,000,000		$	1		—		—
		Common stock		—		200,000,000		$	0.0001		—		30,458,220

Stock_Option_Plan_Tables

Stock Option Plan (Tables)

12 Months Ended

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of weighted-average grant-date fair value of the options

Options

Weighted-

Average

Exercise Price

Per Share

Outstanding, June 30, 2013

1,498,380

11.83

Granted

—

Exercised

—

Forfeited or expired

—

Outstanding, June 30, 2014

1,498,380

11.83

Exercisable, June 30, 2014

1,498,380

11.83

Schedule of the assumptions included in the Black-Scholes model

2013

Risk-free rate of return

2.70%

Expected life

3.0 to 7.5 years

Expected volatility

35%−50%

Expected dividend yield

0.00%

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	12 Months Ended
Employee Benefit Plans (Tables)	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Schedule of changes in projected benefit obligation, plan assets and the funded status	'
		For the Years Ended June 30	2014						2013
		Change in projected benefit obligation
		Projected benefit obligation at beginning of year		$	46,569					$	46,811
		Service cost			2,457						2,729
		Interest cost			2,333						2,058
		Benefits paid			(1,092	)					(796	)
		Actuarial (gain) loss			7,332						(4,233	)
		Projected benefit obligation at end of year		$	57,599					$	46,569



		For the Years Ended June 30	2014						2013
		Change in plan assets
		Fair value of plan assets at beginning of year		$	31,501					$	27,856
		Actual return on plan assets			4,339						1,888
		Employer contributions			4,833						2,553
		Benefits paid			(1,092	)					(796	)
		Fair value of plan assets at end of year		$	39,581					$	31,501
		Funded status at end of year		$	(18,018	)				$	(15,068	)

Schedule of accumulated other comprehensive (income) loss related to the pension plan	'
		For the Years Ended June 30	2014						2013
		Balance at beginning of period		$	12,240					$	17,630
		Amortization of net actuarial loss (gain) and prior service costs			(903	)					(1,405	)
		Current period net actuarial loss (gain)			5,326						(3,985	)
		Net change			4,423						(5,390	)
		Balance at end of period		$	16,663					$	12,240

Schedule of net periodic pension expense	'
		For the Years Ended June 30	2014						2013						2012
		Service cost−benefits earned during the year		$	2,457					$	2,729					$	2,093
		Interest cost on benefit obligation			2,333						2,058						1,957
		Expected return on plan assets			(2,334	)					(2,136	)					(2,040	)
		Amortization of net actuarial loss and prior service costs			904						1,405						251
		Net periodic pension expense		$	3,360					$	4,056					$	2,261


Schedule of significant actuarial assumptions	'
		For the Years Ended June 30	2014			2013		2012
		Discount rate for service and interest	5.00%			4.40%		5.50%
		Expected rate of return on plan assets	7.00%			7.50%		7.50%
		Rate of compensation increase	3.0%−4.5%			3.0%−4.5%		3.0%−4.5%
		Discount rate for year-end benefit obligation	4.50%			5.00%		4.40%

Schedule of estimated future benefit payments, including benefits attributable to future service	'


		For the Years Ended June 30
		2015		$	1,423
		2016			1,655
		2017			1,891
		2018			2,119
		2019			2,362
		2020−2024			15,973

Schedule of weighted-average asset allocation of plan assets	'
			Target			Percentage of Plan Assets
			Allocation			Percentage of Plan Assets
		For the years ended June 30	2015			2014						2013
		Debt securities	10%−35%				20	%					25	%
		Equity securities	20%−50%				35	%					70	%
		Global asset allocation/risk parity(1)	20%−40%				35	%					—
		Other	0%−25%				10	%					5	%



	-1
	The global asset allocation/risk parity category consists of a variety of asset classes including, but not limited to, global bonds, global equities, real estate, commodities and alpha only strategies.
Schedule of fair values of the Company's plan assets by asset category	'
			Fair Value Measurements Using
		As of June 30, 2014	Level 1						Level 2						Level 3				Total
		Cash and cash equivalents		$	138					$	—					$	—			$	138
		Common-collective funds
		Global large cap equities			—						9,909						—				9,909
		Fixed income securities			—						3,935						—				3,935
		Global asset allocations/risk parity			—						5,803						—				5,803
		Mutual funds
		Global Equities			3,925						—						—				3,925
		Fixed income securities			1,913						—						—				1,913
		Global asset allocations/risk parity			3,927						—						—				3,927
		Other
		Fixed income securities			—						—						2,007				2,007
		Global asset allocations/risk parity			—						—						3,954				3,954
		Other			—						—						4,070				4,070
				$	9,903					$	19,647					$	10,031			$	39,581


			Fair Value Measurements Using
		As of June 30, 2013	Level 1						Level 2						Level 3				Total
		Cash and cash equivalents		$	581					$	404					$	—			$	985
		Common-collective funds
		Global large cap equities			6,555						4,743						—				11,298
		Fixed income securities			—						6,730						—				6,730
		Mutual funds
		Global small and mid-cap equities			10,887						—						—				10,887
		Real estate			1,320						—						—				1,320
		Other			—						—						280				280
				$	19,343					$	11,877					$	280			$	31,500

Schedule of summary of the changes in the fair value of level 3 assets	'
		Change in Fair Value Level 3 assets	2014						2013
		Balance at beginning of period		$	280					$	450
		Redemptions			22						—
		Purchases			9,773						51
		Change in fair value			(44	)					(221	)
		Balance at end of period		$	10,031					$	280

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of income (loss) before income taxes	'
		For the Years Ended June 30	2014				2013				2012
		Domestic		$	(26,226	)		$	(6,581	)		$	(10,002	)
		Foreign			32,534				24,429				23,116
		Income (loss) before income taxes		$	6,308			$	17,848			$	13,114

Schedule of components of the provision for income taxes	'
		For the Years Ended June 30	2014				2013				2012
		Current provision (benefit):
		Federal		$	(673	)		$	—			$	66
		State and local			(268	)			391				219
		Foreign			9,087				4,487				7,555
		Total current provision			8,146				4,878				7,840
		Deferred provision (benefit):
		Federal			(1,632	)			(12,160	)			(6,282	)
		State and local			(1,877	)			(616	)			(1,275	)
		Foreign			966				(1,204	)			(290	)
		Change in valuation allowance−domestic			3,509				1,704				7,557
		Change in valuation allowance−foreign			323				355				(1,412	)
		Total deferred provision			1,289				(11,921	)			(1,702	)
		Provision (benefit) for income taxes		$	9,435			$	(7,043	)		$	6,138

Schedule of reconciliations of the Federal statutory rate to the Company's effective tax rate	'
		For the Years Ended June 30	2014				2013				2012
		Federal income tax rate			35	%			35	%			35	%
		State and local taxes, net of federal income tax effect			(0.9	)			1.4				1.1
		Foreign tax rate differential, and change in foreign			(91.0	)			(31.4	)			(33.0	)
		valuation allowance			(91.0	)			(31.4	)			(33.0	)
		Foreign withholding tax			36.5				1.4				2
		Change in federal valuation allowance			43.6				7.8				47.9
		OGR acquisition adjustment			—				(50.7	)			—
		Change in unrecognized tax benefits			(34.9	)			5.4				8.3
		Taxable income not recorded on books			—				0.6				2.4
		Repatriation of foreign earnings			138.7				—				—
		Permanent items			26.1				(7.9	)			(16.1	)
		Other			(3.5	)			(1.1	)			(0.8	)
		Effective tax rate			149.6	%			(39.5	)%			46.8	%
Schedule of the tax effects of significant temporary differences that comprise deferred tax assets and liabilities	'

		As of June 30	2014				2013
		Deferred tax assets:
		Employee related accruals		$	12,417			$	10,709
		Environmental remediation			2,306				2,348
		Net operating loss carry forwards−domestic			19,183				18,790
		Net operating loss carry forwards−foreign			8,729				9,860
		Other			9,540				8,413
					52,175				50,120
		Valuation allowance			(32,892	)			(27,753	)
					19,283				22,367
		Deferred tax liabilities:
		Property, plant and equipment and intangible assets			(13,428	)			(14,645	)
		Unrealized foreign exchange gains			(4,680	)			(4,827	)
		Other			(131	)			(573	)
					(18,239	)			(20,045	)
		Net deferred tax asset (liability)		$	1,044			$	2,322

Schedule of deferred taxes included in the line items of the consolidated balance sheets	'
		As of June 30	2014				2013
		Prepaid expenses and other current assets		$	3,242			$	2,294
		Accrued expenses and other current liabilities			(1,626	)			(1,732	)
		Other assets			3,486				4,755
		Other liabilities			(4,058	)			(2,995	)
				$	1,044			$	2,322

Schedule of the valuation allowance for deferred tax assets	'
		As of June 30	2014				2013				2012
		Balance at beginning of period		$	27,753			$	36,763			$	30,618
		Change in valuation allowance			5,139				2,059				6,145
		Permanent adjustment for Other Comprehensive Income			—				(2,016	)			—
		OGR acquisition adjustments			—				(9,053	)			—
		Balance at end of period		$	32,892			$	27,753			$	36,763

Schedule of the reconciliation of the beginning and ending amount of unrecognized tax benefits	'
		As of June 30	2014				2013				2012
		Unrecognized tax benefits at beginning of		$	12,261			$	6,565			$	6,180
		period		$	12,261			$	6,565			$	6,180
		Additions based on tax positions related to prior periods			1,276				4,996				216
		Additions based on tax positions related to the current period			1,036				404				646
		Reductions related to settlements with tax authorities			(2,215	)			—				—
		Reductions due to lapse of statute of limitations			(5,157	)			—				—
		Exchange effect			219				296				(477	)
		Unrecognized tax benefits at end of period		$	7,420			$	12,261			$	6,565

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum lease commitments	'
		For the Years Ended June 30	Capital				Non-cancellable
		For the Years Ended June 30	leases				operating leases
		2015		$	81			$	4,486
		2016			21				4,033
		2017			8				3,696
		2018			—				3,059
		2019			—				2,641
		Thereafter			—				4,668
		Total minimum lease payments		$	110			$	22,583
		Amounts representing interest			(16	)
		Present value of minimum lease payments		$	94

Derivatives_Tables

Derivatives (Tables)

12 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of significant outstanding derivatives employed to manage market risk and designated as cash flow hedges

Instrument

Hedge

Notional

Fair value as of June 30,

amount at

June 30, 2014

2014

2013

Options

Brazilian Real calls

R$ 78,000

432

365

Options

Brazilian Real puts

(R$ 78,000)

(46

)

(1,004

)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of the fair values of the senior notes	'
		As of June 30	2014			2013
		Fair values
		Term B Loan		$	289,638		$	—
		Senior notes due July 1, 2018			—			322,500
		Term loan payable to Mayflower due December 31, 2016			—			26,968
		Term loan payable to BFI due August 1, 2014			—			10,644

Business_Segments_Tables

Business Segments (Tables)	12 Months Ended
Business Segments (Tables)	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of information regarding reportable segments	'
		For the Years Ended June 30	2014				2013				2012
		Net sales
		Animal Health		$	431,053			$	384,941			$	375,167
		Mineral Nutrition			201,599				203,169				210,091
		Performance Products			59,262				65,041				68,843
				$	691,914			$	653,151			$	654,101
		Adjusted EBITDA
		Animal Health		$	100,280			$	82,997			$	70,456
		Mineral Nutrition			11,636				12,069				13,007
		Performance Products			4,626				2,927				5,132
		Corporate			(25,945	)			(22,239	)			(21,743	)
				$	90,597			$	75,754			$	66,852
		Reconciliation of Adjusted EBITDA to income before income taxes
		Adjusted EBITDA		$	90,597			$	75,754			$	66,852
		Depreciation and amortization			(21,453	)			(19,023	)			(17,527	)
		Loss on insurance claim			(5,350	)			—				—
		Interest expense, net			(32,962	)			(35,629	)			(35,419	)
		Foreign currency gains (losses), net			(1,753	)			(3,103	)			(1,192	)
		Loss on extinguishment of debt			(22,771	)			—				—
		Other income (expense), net			—				(151	)			400
		Income before income taxes		$	6,308			$	17,848			$	13,114



		As of June 30	2014				2013
		Identifiable assets
		Animal Health		$	361,376			$	329,323
		Mineral Nutrition			57,460				64,719
		Performance Products			23,429				21,233
		Corporate			30,058				58,867
				$	472,323			$	474,142

Geographic_Information_Tables

Geographic Information (Tables)	12 Months Ended
Geographic Information (Tables)	Jun. 30, 2014
Segments, Geographical Areas [Abstract]	'
Schedule of information about geographic operations	'

		For the Years Ended June 30	2014			2013			2012
		Net sales
		United States		$	435,414		$	414,768		$	424,373
		Israel			89,739			93,248			101,301
		Latin America and Canada			84,775			68,575			61,407
		Europe and Africa			38,563			32,501			30,087
		Asia/Pacific			43,423			44,059			36,933
				$	691,914		$	653,151		$	654,101


Schedule of geographic information regarding property, plant and equipment, net	'

		As of June 30	2014			2013
		Property, plant and equipment, net
		United States		$	40,926		$	40,601
		Israel			33,426			30,837
		Brazil			32,946			30,988
		Other			1,861			1,996
				$	109,159		$	104,422

Selected_Quarterly_Results_of_1

Selected Quarterly Results of Operations Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of selected quarterly results of operations data	'
	Quarters																	Year
		For the Periods Ended	September 30,				December 31,				March 31,				June 30,				June 30,
		For the Periods Ended	2013				2013				2014				2014				2014
			(in thousands)
		Net sales
		Animal Health		$	101,171			$	107,966			$	107,808			$	114,108			$	431,053
		Mineral Nutrition			46,186				50,633				49,901				54,879				201,599
		Performance Products			14,871				14,143				15,558				14,690				59,262
		Total net sales			162,228				172,742				173,267				183,677				691,914
		Cost of goods sold			112,716				121,586				120,425				129,412				484,139
		Gross profit			49,512				51,156				52,842				54,265				207,775
		Selling, general and administrative expenses			33,115				34,138				35,520				41,208				143,981
		Operating income (loss)			16,397				17,018				17,322				13,057				63,794
		Interest expense			8,779				8,787				8,810				6,705				33,081
		Interest (income)			(44	)			(68	)			(66	)			59				(119	)
		Foreign currency (gains) losses, net			648				1,165				275				(335	)			1,753
		Loss on extinguishment of debt			—				—				—				22,771				22,771
		Income (loss) before income taxes			7,014				7,134				8,303				(16,143	)			6,308
		Provision (benefit) for income taxes			1,171				4,832				1,933				1,499				9,435
		Net income (loss)		$	5,843			$	2,302			$	6,370			$	(17,642	)		$	(3,127	)
		Net income per share−basic and diluted		$	0.19			$	0.08			$	0.21			$	(0.47	)		$	(0.10	)
		Adjusted EBITDA
		Animal Health		$	24,107			$	24,522			$	25,505			$	26,146			$	100,280
		Mineral Nutrition			2,460				2,878				2,807				3,491				11,636
		Performance Products			1,096				1,103				906				1,521				4,626
		Corporate			(6,065	)			(6,193	)			(6,774	)			(6,913	)			(25,945	)
		Adjusted EBITDA		$	21,598			$	22,310			$	22,444			$	24,245			$	90,597



			Quarters																Year
		For the Periods Ended	September 30,				December 31,				March 31,				June 30,				June 30,
		For the Periods Ended	2012				2012				2013				2013				2013
			(in thousands)
		Net sales
		Animal Health		$	96,128			$	94,236			$	93,883			$	100,694			$	384,941
		Mineral Nutrition			49,792				52,892				51,757				48,728				203,169
		Performance Products			16,186				17,031				17,045				14,779				65,041
		Total net sales			162,106				164,159				162,685				164,201				653,151
		Cost of goods sold			120,240				120,973				116,929				116,045				474,187
		Gross profit			41,866				43,186				45,756				48,156				178,964
		Selling, general and administrative expenses			28,657				29,030				31,295				33,251				122,233
		Operating income (loss)			13,209				14,156				14,461				14,905				56,731
		Interest expense			8,893				8,969				8,901				9,008				35,771
		Interest (income)			(68	)			(14	)			(26	)			(34	)			(142	)
		Foreign currency (gains) losses, net			168				126				838				1,971				3,103
		Other (income) expense, net			(12	)			58				482				(377	)			151
		Income (loss) before income taxes			4,228				5,017				4,266				4,337				17,848
		Provision (benefit) for income taxes			1,569				(7,056	)			86				(1,642	)			(7,043	)
		Net income (loss)		$	2,659			$	12,073			$	4,180			$	5,979			$	24,891
		Net income per share−basic and diluted		$	0.09			$	0.4			$	0.14			$	0.2			$	0.82
		Adjusted EBITDA
		Animal Health		$	20,103			$	19,516			$	20,334			$	23,044			$	82,997
		Mineral Nutrition			2,690				3,175				3,439				2,765				12,069
		Performance Products			1,145				1,826				1,577				(1,621	)			2,927
		Corporate			(6,033	)			(5,739	)			(5,930	)			(4,537	)			(22,239	)
		Adjusted EBITDA		$	17,905			$	18,778			$	19,420			$	19,651			$	75,754

Initial_Public_Offering_and_Re2

Initial Public Offering and Refinancing (Details) (Senior Notes, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Initial Public Offering And Refinancing [Line Items]	'
Redemption premium on Senior Notes	$17,184
Loss on extinguishment of debt	22,771
BFI	'
Initial Public Offering And Refinancing [Line Items]	'
Write-off of original issue discount related to Senior Notes and BFI term loan	2,123
Mayflower And Bfi	'
Initial Public Offering And Refinancing [Line Items]	'
Write-off of capitalized debt issuance costs related to Senior Notes, Mayflower term loan, BFI term loan and cancelled domestic senior credit facility and other items	$3,464

Initial_Public_Offering_and_Re3

Initial Public Offering and Refinancing (Detail Textuals) (USD $)	12 Months Ended	0 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	16-May-14	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014	Apr. 16, 2014
		Senior Notes	Senior Domestic Credit Facility	Credit Agreement	Credit Agreement	Mayflower	BFI	IPO	IPO	IPO	Over-Allotment Option
				Bank of America	Bank of America	Term loan payable	Term loan payable		Class A common stock	Class A common stock	Class A common stock
				Term B Loans	Credit Facility					Mayflower	Mayflower
Initial Public Offering And Refinancing [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Initial public offering completed for number of common stock	'	'	'	'	'	'	'	'	14,657,200	'	'
Number of shares issued and sold	'	'	'	'	'	'	'	'	8,333,333	6,323,867	1,911,808
Price per share	'	'	'	'	'	'	'	'	$15	'	'
Proceeds from offering	$114,429	'	'	'	'	'	'	'	$114,429	'	'
Underwriting discount	'	'	'	'	'	'	'	'	8,438	'	'
Offering expense payable	'	'	'	'	'	'	'	'	2,133	'	'
Stock split	'	'	'	'	'	'	'	'0.442-for-1	'	'	'
Aggregate principal amount	'	'	'	290,000	100,000	'	'	'	'	'	'
Retirement of debt	'	$300,000	$36,000	'	'	$24,000	$10,000	'	'	'	'
Percentage of interest rate	'	9.25%	'	'	'	'	'	'	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Detail Textuals)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
	Cash Flows From Operating Activities	Cash Flows From Investing Activities	Income Before Income Taxes	Accounts Receivable	Accounts Receivable
				Customer	Customer
Significant Accounting Policies [Line Items]	'	'	'	'	'
Percentage of accounts receivable	'	'	'	21.00%	24.00%
Number of largest customers	'	'	'	10	10
Error corrected for prior period	'1,022	'106	'358	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Detail Textuals 1)	12 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Line Items]	'
Depreciation methods	'straight-line method
Stock options and warrant	'
Significant Accounting Policies [Line Items]	'
Potential dilutive common shares	296,162
Building and Improvements \| Minimum	'
Significant Accounting Policies [Line Items]	'
Estimated useful lives	'8 years
Building and Improvements \| Maximum	'
Significant Accounting Policies [Line Items]	'
Estimated useful lives	'25 years
Machinery and Equipment \| Minimum	'
Significant Accounting Policies [Line Items]	'
Estimated useful lives	'3 years
Machinery and Equipment \| Maximum	'
Significant Accounting Policies [Line Items]	'
Estimated useful lives	'16 years
Computer Software	'
Significant Accounting Policies [Line Items]	'
Finite lived intangible assets amortization period	'7 years
Amortization method	'straight-line basis

Statements_of_OperationsAdditi2

Statements of Operations-Additional Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Depreciation and amortization	'	'	'
Depreciation of property, plant and equipment	$16,439	$14,917	$14,425
Amortization of intangible assets	4,897	4,106	3,048
Amortization of other assets	117	'	54
Depreciation and amortization	21,453	19,023	17,527
Research and development expenditures	$8,212	$6,638	$7,189

Statements_of_OperationsAdditi3

Statements of Operations-Additional Information (Detail Textuals 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Statements Of Operations Additional Information [Abstract]	'	'	'
Expected amortization of intangibles, 2015	$4,210	'	'
Expected amortization of intangibles, 2016	3,699	'	'
Expected amortization of intangibles, 2017	2,864	'	'
Expected amortization of intangibles, 2018	2,691	'	'
Expected amortization of intangibles, 2019	2,656	'	'
Expected amortization of intangibles, thereafter	13,683	'	'
Depreciation and amortization of capitalized software costs	$2,657	$2,159	$2,362

Balance_SheetsAdditional_Infor2

Balance Sheets-Additional Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013		Jun. 30, 2012
Accounts receivable, net	'	'		'
Trade accounts receivable	$115,093	$99,795		'
Allowance for doubtful accounts	-1,235	-658		-1,041	[1]
Trade accounts receivable, net	113,858	99,137		'
Allowance for doubtful accounts	'	'		'
Balance at beginning of period	658	1,041	[1]	1,029	[1]
Provision for bad debts	226	-124		-115	[1]
Effect of changes in exchange rates	351	-265		127	[1]
Bad debt write-offs (recovery)	'	6		'
Balance at end of period	1,235	658		1,041	[1]
Inventories, net	'	'		'
Raw materials	44,306	36,589		'
Work-in-process	7,518	7,541		'
Finished goods	91,360	95,902		'
Inventory, net	143,184	140,032		'
Property, plant and equipment, net	'	'		'
Property, plant and equipment, gross	233,667	212,953		'
Accumulated depreciation	-124,508	-108,531		'
Property, plant and equipment, net	109,159	104,422		'
Land	'	'		'
Property, plant and equipment, net	'	'		'
Property, plant and equipment, gross	9,773	9,746		'
Buildings and improvements	'	'		'
Property, plant and equipment, net	'	'		'
Property, plant and equipment, gross	51,364	46,960		'
Machinery and equipment	'	'		'
Property, plant and equipment, net	'	'		'
Property, plant and equipment, gross	$172,530	$156,247		'

[1]	For the year ended June 30, 2012, the beginning balance for allowance for doubtful accounts was $1,029, the provision for bad debts was ($115) and the effect of changes in exchange rates was $127, resulting in an ending balance for allowance for doubtful accounts of $1,041.

Balance_SheetsAdditional_Infor3

Balance Sheets-Additional Information - Parentheticals (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013		Jun. 30, 2012
Balance Sheets Additional Information [Abstract]	'	'		'
Balance at beginning of period	$658	$1,041	[1]	$1,029	[1]
Provision for bad debts	226	-124		-115	[1]
Effect of changes in exchange rates	351	-265		127	[1]
Balance at end of period	$1,235	$658		$1,041	[1]

[1]	For the year ended June 30, 2012, the beginning balance for allowance for doubtful accounts was $1,029, the provision for bad debts was ($115) and the effect of changes in exchange rates was $127, resulting in an ending balance for allowance for doubtful accounts of $1,041.

Balance_SheetsAdditional_Infor4

Balance Sheets-Additional Information (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	$61,232	$61,590	'
Accumulated amortization	-31,429	-26,435	'
Intangibles, net	29,803	35,155	'
Other assets	'	'	'
Goodwill	12,613	12,613	'
Advances to and investments in equity method investees	5,619	3,515	'
Insurance investments	4,626	4,456	'
Deferred financing fees	5,199	5,212	'
Deferred income taxes	3,486	4,755	'
Insurance claim receivable	'	5,350	'
Other	2,529	2,278	'
Other assets, total	34,072	38,179	'
Goodwill roll-forward	'	'	'
Balance at beginning of period	12,613	1,717	'
OGR acquisition	'	10,896	'
Balance at end of period	12,613	12,613	'
Accrued expenses and other current liabilities	'	'	'
Employee related accruals	20,813	17,823	'
Interest	'	13,875	'
Commissions and rebates	2,973	3,196	'
Insurance related	1,395	1,286	'
Professional fees	4,229	4,064	'
Deferred consideration on acquisitions	1,420	1,250	'
Product liability claims	5,286	'	'
Other accrued liabilities	13,745	15,944	'
Accrued expenses and other current liabilities, total	49,861	57,438	'
Other liabilities	'	'	'
Pension and other retirement benefits	31,025	26,021	'
Long term and deferred income taxes	14,282	17,580	'
Deferred consideration on acquisitions	2,879	5,009	'
Product liability claims	'	5,600	'
Other long term liabilities	10,128	7,926	'
Other liabilities, total	58,314	62,136	'
Accumulated other comprehensive income (loss)	'	'	'
Derivative instruments	386	-639	'
Foreign currency translation adjustment	-1,409	-2,519	'
Unrecognized net pension gains (losses)	-16,663	-12,240	-17,630
Income tax (provision) benefit on derivative instruments	63	63	'
Income tax (provision) benefit on pension gains (losses)	-2,437	-2,437	'
Accumulated other comprehensive income (loss)	-20,060	-17,772	'
Medicated feed additive product registrations	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	11,792	12,115	'
Accumulated amortization	-11,039	-10,778	'
Weighted-Average Useful Life (Years)	'10 years	'	'
Rights to sell in international markets	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	4,292	4,292	'
Accumulated amortization	-4,292	-3,861	'
Weighted-Average Useful Life (Years)	'10 years	'	'
Customer relationships	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	10,702	10,691	'
Accumulated amortization	-4,265	-3,203	'
Weighted-Average Useful Life (Years)	'13 years	'	'
Technology	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	28,259	28,259	'
Accumulated amortization	-6,510	-3,729	'
Weighted-Average Useful Life (Years)	'11 years	'	'
Distribution agreements	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	3,447	3,493	'
Accumulated amortization	-3,309	-3,179	'
Weighted-Average Useful Life (Years)	'4 years	'	'
Trade names, trademarks and other	'	'	'
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'	'	'
Intangibles	2,740	2,740	'
Accumulated amortization	($2,014)	($1,685)	'
Weighted-Average Useful Life (Years)	'5 years	'	'

Balance_SheetsAdditional_Infor5

Balance Sheets-Additional Information (Detail Textuals) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Additional Information Of Balance Sheet [Line Items]	'	'
Equity Method Investments	$5,619	$3,515
Net equipment under capital leases	142	152
Accumulated depreciation net equipment under capital leases	79	39
Accumulated depreciation	9,019	9,154
Construction-in-progress	4,782	5,543
Animal Health	'	'
Additional Information Of Balance Sheet [Line Items]	'	'
Equity Method Investments	$5,140	$4,734

Acquisition_Allocation_of_purc

Acquisition - Allocation of purchase price after valuation adjustments (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Dec. 20, 2012
In Thousands, unless otherwise specified				Prince Agri Products Inc
				OmniGen Research, LLC
Assets	'	'	'	'
Property, plant and equipment	'	'	'	$1,202
Intangibles	'	'	'	23,781
Goodwill	12,613	12,613	1,717	10,896
Total assets	'	'	'	35,879
Liabilities	'	'	'	'
Other current and long-term liabilities	'	'	'	13,129
Total liabilities	'	'	'	13,129
Net assets acquired	'	'	'	$22,750

Acquisition_Summary_of_unaudit

Acquisition - Summary of unaudited pro forma consolidated results of operations (Details 1) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Business Combinations [Abstract]	'	'
Net sales	$653,151	$654,101
Net income (loss)	25,989	9,170
Net income (loss) per share-basic and diluted (in dollars per share)	$0.85	$0.30
Adjusted EBITDA	$77,731	$70,804

Acquisition_Detail_Textuals

Acquisition (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012	Dec. 20, 2012	Jun. 30, 2014
			Prince Agri Products Inc	Prince Agri Products Inc
			OmniGen Research, LLC	OmniGen Research, LLC
Business Acquisition [Line Items]	'	'	'	'
Membership interest acquired	'	'	100.00%	'
Total purchase price	'	'	$22,750	'
Initial cash payment	18,692	3,384	18,500	'
Deferred payments	'	'	4,250	'
Deferred payments scheduled on or before December 20, 2013	'	'	1,000	'
Deferred payments scheduled on or before December 20, 2014	'	'	1,000	'
Deferred payments scheduled on or before December 20, 2015	'	'	1,000	'
Deferred payments scheduled on or before December 20, 2016	'	'	$1,250	'
Interest rate on deferred payments	'	'	5.00%	'
Remaining amortization period of identifiable intangibles	'	'	'	'12 years

Debt_Summary_of_longterm_debt_

Debt - Summary of long-term debt (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Debt Instrument [Line Items]	'	'
Capitalized lease obligations	$94	$132
Long-term debt and capital lease obligations, gross	290,094	334,132
Unamortized debt discount	-703	-2,528
Long-term debt and capital lease obligations, net	289,391	331,604
Less: current maturities	-2,969	-64
Long-term debt	286,422	331,540
Term B Loans	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	290,000	'
Senior notes	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	'	300,000
Term loan payable \| Mayflower	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	'	24,000
Term loan payable \| BFI	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	'	$10,000

Debt_Aggregate_maturities_of_l

Debt - Aggregate maturities of long-term debt (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Debt Disclosure [Abstract]	'	'
2015	$2,969	'
2016	2,918	'
2017	2,907	'
2018	2,900	'
2019	2,900	'
Thereafter	275,500	'
Total	$290,094	$334,132

Debt_Detail_Textuals

Debt (Detail Textuals) (USD $)

12 Months Ended

0 Months Ended

Jun. 30, 2014

Apr. 16, 2014

Credit Facility

Term B Loans And Revolving Credit Facility

Credit Agreement

Israel subsidiaries

LIBOR

Prime Rate

Bank of America

Israel subsidiaries

Term B Loans

Credit Facility

Term B Loans And Revolving Credit Facility

LIBOR

Base Rate

LIBOR

Base Rate

LIBOR

Base Rate

Debt Instrument [Line Items]

Aggregate principal amount

$290,000,000

$100,000,000

Basis for effective rate

'a base rate determined by reference to the highest of (a) the rate as publicly announced from time to time by Bank of America as its "prime rate," (b) the federal funds effective rate plus 0.50% and (c) one-month LIBOR plus 1.00

a Eurocurrency rate determined by reference to LIBOR with a term as selected by the Company, of one day or one, two, three or six months (or twelve months or any shorter amount of time if consented to by all of the lenders under the applicable loan)

Interest rate, description

'2.50% or 2.75%

'1.50% or 1.75%

Applicable interest rates

3.00%

2.00%

Applicable floor rates

1.00%

Quarterly principal payments

725,000

Maturity dates

31-Dec-14

15-Apr-21

15-Apr-19

Par value in percentage

99.75%

Proceeds from term loan

284,740,000

Original issue discount and issuance cost

5,260,000

Outstanding borrowings

17,140,000

Available borrowings under credit lines

82,860,000

EBITDA leverage ratio, Beginning September 30, 2014 through June 30, 2015

'4.50:1.00

EBITDA leverage ratio, Thereafter

'4.25:1.00

Aggregate available credit facilities

$15,000,000

Description of variable rate basis

'LIBOR

'Prime

Percentage of credit facility interest rate

2.25%

1.00%

Preferred_and_Common_Shares_Su

Preferred and Common Shares - Summary of preferred and common shares (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Class of Stock [Line Items]	'	'
Preferred stock, shares authorized	16,000,000	1,000,000
Preferred stock, par value (in dollars per share)	$0.00	$1
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, shares authorized	'	200,000,000
Common stock, par value (in dollars per share)	'	$0.00
Common stock, shares issued	'	30,458,220
Common stock, shares outstanding	'	30,458,220
Class A common stock	'	'
Class of Stock [Line Items]	'	'
Common stock, shares authorized	300,000,000	'
Common stock, par value (in dollars per share)	$0.00	'
Common stock, shares issued	17,442,953	'
Common stock, shares outstanding	17,442,953	'
Class B common stock	'	'
Class of Stock [Line Items]	'	'
Common stock, shares authorized	30,000,000	'
Common stock, par value (in dollars per share)	$0.00	'
Common stock, shares issued	21,348,600	'
Common stock, shares outstanding	21,348,600	'

Preferred_and_Common_Shares_De

Preferred and Common Shares (Detail Textuals) (USD $)	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jul. 31, 2014	Jul. 31, 2014	Aug. 01, 2014	Jun. 30, 2014
		BFI	Class A common stock	Class A common stock	Class B common stock	Class B common stock	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
							Class A common stock	Class B common stock	Class B common stock	Class B common stock
									BFI	BFI
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Common stock holder entiltled to vote per share	'	'	'One vote	'	'10 votes	'	'	'	'	'
Common stock right to register sale of common stock shares	'	'	2,800,000	'	'	'	'	'	'	'
Percentage of outstanding shares of Class B common stock and Class A common stock held by BFI	'	15.00%	'	'	'	'	'	'	'	'
Number of warrants to purchase common stock	'	'	'	'	'	'	'	'	386,750	'
Exercise price	'	'	'	'	'	'	'	'	11.83	'
Net issuance of common stock	30,458,220	'	17,442,953	'	21,348,600	'	'	'	163,675	21,500,000
Dividend payable per share	'	'	'	'	'	'	$0.10	$0.10	'	'
Dividends payable, record date	'	'	'	'	'	'	3-Sep-14	3-Sep-14	'	'
Dividends payable, date to be paid	'	'	'	'	'	'	24-Sep-14	24-Sep-14	'	'

Stock_Option_Plan_Details

Stock Option Plan (Details) (USD $)	12 Months Ended
Stock Option Plan (Details) (USD $)	Jun. 30, 2014
Shares	'
Outstanding, June 30, 2013	1,498,380
Granted	'
Exercised	'
Forfeited or expired	'
Outstanding, June 30, 2014	1,498,380
Exercisable, June 30, 2014	1,498,380
Weighted- Average Exercise Price Per Share	'
Outstanding, June 30, 2013	$11.83
Granted	'
Exercised	'
Forfeited or expired	'
Outstanding, June 30, 2014	$11.83
Exercisable, June 30, 2014	$11.83

Stock_Option_Plan_Summary_of_s

Stock Option Plan - Summary of several assumptions for determining fair value of option (Details 1) (Stock Option, Incentive Plan 2008)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Risk-free rate of return	2.70%
Expected dividend yield	0.00%
Minimum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected life	'3 years
Expected volatility	35.00%
Maximum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected life	'7 years 6 months
Expected volatility	50.00%

Stock_Option_Plan_Detail_Textu

Stock Option Plan (Detail Textuals) (USD $)	12 Months Ended					1 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Mar. 12, 2008	Jun. 30, 2014	Apr. 29, 2013	Feb. 26, 2009	Jun. 30, 2014
		Stock Option	Stock Option	Stock Option	Stock Option	Non Qualified Stock Option	Non Qualified Stock Option	Non Qualified Stock Option
			Incentive Plan 2008	Incentive Plan 2008	Incentive Plan 2008	Incentive Plan 2008	Incentive Plan 2008	Incentive Plan 2008
					Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Common shares available for grants	'	'	'	6,630,000	5,131,620	'	'	'
Stock options exercise price	'	'	'	'	'	$11.83	$11.83	'
Weighted-average grant-date fair value of the options	'	'	'	'	'	'	'	$0.99
Method used for valuation of fair value	'	'	'Black-Scholes option pricing model	'	'	'	'	'
Number of shares vested	'	374,595	'	'	'	'	'	'
Aggregate intrinsic value	'	$15,164	'	'	'	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Detail Textuals) (Mr. Bendheim, Compensation And Benefit For Services, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Mr. Bendheim \| Compensation And Benefit For Services	'	'	'
Related Party Transaction [Line Items]	'	'	'
Aggregate compensation and benefits	$1,764	$1,858	$1,655

Employee_Benefit_Plans_Changes

Employee Benefit Plans - Changes in projected benefit obligation, plan assets and funded status (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Change in projected benefit obligation	'	'	'
Projected benefit obligation at beginning of year	$46,569	$46,811	'
Service cost	2,457	2,729	2,093
Interest cost	2,333	2,058	1,957
Benefits paid	-1,092	-796	'
Actuarial (gain) loss	7,332	-4,233	'
Projected benefit obligation at end of year	57,599	46,569	46,811
Change in plan assets	'	'	'
Fair value of plan assets at beginning of year	31,501	27,856	'
Actual return on plan assets	4,339	1,888	'
Employer contributions	4,833	2,553	'
Benefits paid	-1,092	-796	'
Fair value of plan assets at end of year	39,581	31,501	27,856
Funded status at end of year	($18,018)	($15,068)	'

Employee_Benefit_Plans_Change_

Employee Benefit Plans - Change in Accumulated Other Comprehensive (Income) Loss (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Plan Change In Accumulated Other Comprehensive Income Loss [Roll Forward]	'	'	'
Balance at beginning of period	$12,240	$17,630	'
Amortization of net actuarial loss (gain) and prior service cost	-904	-1,405	-251
Current period net actuarial loss (gain)	5,326	-3,985	'
Net change	4,423	-5,390	'
Balance at end of period	$16,663	$12,240	$17,630

Employee_Benefit_Plans_Net_per

Employee Benefit Plans - Net periodic pension expense (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'
Service cost - benefits earned during the year	$2,457	$2,729	$2,093
Interest cost on benefit obligation	2,333	2,058	1,957
Expected return on plan assets	-2,334	-2,136	-2,040
Amortization of net actuarial loss and prior service costs	904	1,405	251
Net periodic pension expense	$3,360	$4,056	$2,261

Employee_Benefit_Plans_Signifi

Employee Benefit Plans - Significant actuarial assumptions for plan (Details 3)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Discount rate for service and interest	5.00%	4.40%	5.50%
Expected rate of return on plan assets	7.00%	7.50%	7.50%
Discount rate for year-end benefit obligation	4.50%	5.00%	4.40%
Minimum	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Rate of compensation increase	3.00%	3.00%	3.00%
Maximum	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Rate of compensation increase	4.50%	4.50%	4.50%

Employee_Benefit_Plans_Estimat

Employee Benefit Plans - Estimated future benefit payments including benefits attributable to future service (Details 4) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
2015	$1,423
2016	1,655
2017	1,891
2018	2,119
2019	2,362
2020-2024	$15,973

Employee_Benefit_Plans_Plans_t

Employee Benefit Plans - Plan's target asset allocations and weighted average asset allocation of plan assets (Details 5)	12 Months Ended
	Jun. 30, 2014		Jun. 30, 2013
Debt securities	'		'
Defined Benefit Plan Disclosure [Line Items]	'		'
Target allocation for 2015 minimum	10.00%		'
Target allocation for 2015 maximum	35.00%		'
Percentage of Plan Assets	20.00%		25.00%
Equity securities	'		'
Defined Benefit Plan Disclosure [Line Items]	'		'
Target allocation for 2015 minimum	20.00%		'
Target allocation for 2015 maximum	50.00%		'
Percentage of Plan Assets	35.00%		70.00%
Global asset allocation/risk parity	'		'
Defined Benefit Plan Disclosure [Line Items]	'		'
Target allocation for 2015 minimum	20.00%	[1]	'
Target allocation for 2015 maximum	40.00%	[1]	'
Percentage of Plan Assets	35.00%	[1]	'	[1]
Other	'		'
Defined Benefit Plan Disclosure [Line Items]	'		'
Target allocation for 2015 minimum	0.00%		'
Target allocation for 2015 maximum	25.00%		'
Percentage of Plan Assets	10.00%		5.00%

[1]	The global asset allocation/risk parity category consists of a variety of asset classes including, but not limited to, global bonds, global equities, real estate, commodities and alpha only strategies.

Employee_Benefit_Plans_Fair_va

Employee Benefit Plans - Fair values of plan assets by asset category (Details 6) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	$39,581	$31,501	$27,856
Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	9,903	19,343	'
Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	19,647	11,877	'
Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	10,031	280	450
Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	39,591	31,500	'
Cash and cash equivalents \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	138	581	'
Cash and cash equivalents \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	404	'
Cash and cash equivalents \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Cash and cash equivalents \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	138	985	'
Common-collective funds - Global large cap equities \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	6,555	'
Common-collective funds - Global large cap equities \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	9,909	4,743	'
Common-collective funds - Global large cap equities \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Common-collective funds - Global large cap equities \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	9,909	11,298	'
Common-collective funds - Fixed income securities \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Common-collective funds - Fixed income securities \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,935	6,730	'
Common-collective funds - Fixed income securities \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Common-collective funds - Fixed income securities \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,935	6,730	'
Common-collective funds - Global asset allocations/risk parity \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Common-collective funds - Global asset allocations/risk parity \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	5,803	'	'
Common-collective funds - Global asset allocations/risk parity \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Common-collective funds - Global asset allocations/risk parity \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	5,803	'	'
Mutual funds - Global Equities \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,925	10,887	'
Mutual funds - Global Equities \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Global Equities \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Global Equities \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,925	10,887	'
Mutual funds - Fixed income securities \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	1,913	'	'
Mutual funds - Fixed income securities \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Fixed income securities \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Fixed income securities \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	1,913	'	'
Mutual funds - Global asset allocations/risk parity \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,927	'	'
Mutual funds - Global asset allocations/risk parity \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Global asset allocations/risk parity \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Global asset allocations/risk parity \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,927	'	'
Mutual funds - Real estate \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	1,320	'
Mutual funds - Real estate \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Real estate \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Mutual funds - Real estate \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	1,320	'
Other - Fixed income securities \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other - Fixed income securities \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other - Fixed income securities \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	2,007	'	'
Other - Fixed income securities \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	2,007	'	'
Other - Global asset allocations/risk parity \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other - Global asset allocations/risk parity \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other - Global asset allocations/risk parity \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,954	'	'
Other - Global asset allocations/risk parity \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	3,954	'	'
Other \| Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other \| Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	'	'	'
Other \| Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	4,070	280	'
Other \| Total	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair values of plan assets by asset category	$4,070	$280	'

Employee_Benefit_Plans_Change_1

Employee Benefit Plans - Change in Fair Value of Level 3 Assets (Details 7) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Level 3	Level 3
Change in Fair Value Level 3 assets	'	'	'	'	'
Fair value of plan assets at beginning of year	$39,581	$31,501	$27,856	$280	$450
Redemptions	'	'	'	22	'
Purchases	'	'	'	9,773	51
Change in fair value	'	'	'	-44	-221
Fair value of plan assets at end of year	$39,581	$31,501	$27,856	$10,031	$280

Employee_Benefit_Plans_Detail_

Employee Benefit Plans (Detail Textuals) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
	Jun. 30, 2014	Other liabilities	Other liabilities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'
Accumulated benefit obligation	'	$51,980,000	$41,859,000
Contribution to pension plan during fiscal year	6,815,000	'	'
Amortization of unrecognized net actuarial (gain) loss and prior service cost	1,228,000	'	'
Noncollable corporate bond par value outstanding	$250,000,000	'	'
Cash and cash equivalents fair value assumptions input (in dollars per share)	$1	'	'

Employee_Benefit_Plans_Detail_1

Employee Benefit Plans (Detail Textuals 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Term of vesting in employer contributions	'after two years of service	'	'
401(k) retirement savings plan	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Description of the basis for determining contributions	'	'	'
Description of the basis for determining contributions	Matching contribution equal to 100% of the first 1% of an employee’s contribution and make a matching contribution equal to 50% of the next 5% of an employee’s contribution. Employees hired on or after January 1, 2014, receive a non-elective Company contribution of 3% and are eligible to receive an additional discretionary payment between 1% and 4%, depending on age and years of service, provided that such payments comply with mandatory non-discrimination testing.	'	'
Maximum pre-tax contribution to the plan	60.00%	'	'
Defined contribution plan, employer contribution amount	$1,281	$1,175	$1,010
Supplemental executive retirement benefits, international retirement plans and other employee benefit plans	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Expenses under plan	3,832	2,817	3,163
Supplemental executive retirement benefits, international retirement plans and other employee benefit plans \| Other liabilities	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Pension and other postretirement benefit plans, liabilities	$13,007	$10,953	'

Income_Taxes_Income_loss_befor

Income Taxes - Income (loss) before income taxes (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Domestic	'	'	'	'	'	'	'	'	($26,226)	($6,581)	($10,002)
Foreign	'	'	'	'	'	'	'	'	32,534	24,429	23,116
Income (loss) before income taxes	($16,143)	$8,303	$7,134	$7,014	$4,337	$4,266	$5,017	$4,228	$6,308	$17,848	$13,114

Income_Taxes_Components_of_pro

Income Taxes - Components of provision for income taxes (Details 1) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Current provision (benefit):	'	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	($673)	'	$66
State and local	'	'	'	'	'	'	'	'	-268	391	219
Foreign	'	'	'	'	'	'	'	'	9,087	4,487	7,555
Total current provision	'	'	'	'	'	'	'	'	8,146	4,878	7,840
Deferred provision (benefit):	'	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	-1,632	-12,160	-6,282
State and local	'	'	'	'	'	'	'	'	-1,877	-616	-1,275
Foreign	'	'	'	'	'	'	'	'	966	-1,204	-290
Change in valuation allowance-domestic	'	'	'	'	'	'	'	'	3,509	1,704	7,557
Change in valuation allowance-foreign	'	'	'	'	'	'	'	'	323	355	-1,412
Total deferred provision	'	'	'	'	'	'	'	'	1,289	-12,035	-2,392
Provision (benefit) for income taxes	$1,499	$1,933	$4,832	$1,171	($1,642)	$86	($7,056)	$1,569	$9,435	($7,043)	$6,138

Income_Taxes_Reconciliations_o

Income Taxes - Reconciliations of Federal statutory rate to effective tax rate (Details 2)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'
Federal income tax rate	35.00%	35.00%	35.00%
State and local taxes, net of federal income tax effect	-0.90%	1.40%	1.10%
Foreign tax rate differential, and change in foreign valuation allowance	-91.00%	-31.40%	-33.00%
Foreign withholding tax	36.50%	1.40%	2.00%
Change in federal valuation allowance	43.60%	7.80%	47.90%
OGR acquisition adjustment	'	-50.70%	'
Change in unrecognized tax benefits	-34.90%	5.40%	8.30%
Taxable income not recorded on books	'	0.60%	2.40%
Repatriation of foreign earnings	138.70%	'	'
Permanent items	26.10%	-7.90%	-16.10%
Other	-3.50%	-1.10%	-0.80%
Effective tax rate	149.60%	-39.50%	46.80%

Income_Taxes_Tax_effects_of_si

Income Taxes - Tax effects of significant temporary differences of deferred tax assets and liabilities (Details 3) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Deferred tax assets:	'	'	'	'
Employee related accruals	$12,417	$10,709	'	'
Environmental remediation	2,306	2,348	'	'
Net operating loss carry forwards-domestic	19,183	18,790	'	'
Net operating loss carry forwards-foreign	8,729	9,860	'	'
Other	9,540	8,413	'	'
Deferred tax assets, gross	52,175	50,120	'	'
Valuation allowance	-32,892	-27,753	-36,763	-30,618
Deferred tax assets, net of valuation allowance	19,283	22,367	'	'
Deferred tax liabilities:	'	'	'	'
Property, plant and equipment and intangible assets	-13,428	-14,645	'	'
Unrealized foreign exchange gains	-4,680	-4,827	'	'
Other	-131	-573	'	'
Deferred tax liabilities, net	-18,239	-20,045	'	'
Net deferred tax asset (liability)	$1,044	$2,322	'	'

Income_Taxes_Deferred_taxes_in

Income Taxes - Deferred taxes included in consolidated balance sheets (Details 4) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Net deferred tax asset (liability)	$1,044	$2,322
Prepaid expenses and other current assets	'	'
Net deferred tax asset (liability)	3,242	2,294
Accrued expenses and other current liabilities	'	'
Net deferred tax asset (liability)	-1,626	-1,732
Other assets	'	'
Net deferred tax asset (liability)	3,486	4,755
Other liabilities	'	'
Net deferred tax asset (liability)	($4,058)	($2,995)

Income_Taxes_Valuation_allowan

Income Taxes - Valuation allowance for deferred tax assets (Details 5) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'
Balance at beginning of period	$27,753	$36,763	$30,618
Change in valuation allowance	5,139	2,059	6,145
Permanent adjustment for Other Comprehensive Income	'	-2,016	'
OGR acquisition adjustments	'	-9,053	'
Balance at end of period	$32,892	$27,753	$36,763

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of unrecognized tax benefits (Details 6) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Unrecognized tax benefits at beginning of period	$12,261	$6,565	$6,180
Additions based on tax positions related to prior periods	1,276	4,996	216
Additions based on tax positions related to the current period	1,036	404	646
Reductions related to settlements with tax authorities	-2,215	'	'
Reductions due to lapse of statute of limitations	-5,157	'	'
Exchange effect	219	296	-477
Unrecognized tax benefits at end of period	$7,420	$12,261	$6,565

Income_Taxes_Detail_Textuals

Income Taxes (Detail Textuals) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Valuation Allowance [Line Items]	'	'	'	'
Undistributed earnings of foreign subsidiaries	$93,622	'	'	'
Dividend received from subsidiary	25,000	'	'	'
Valuation allowance for deferred tax assets	32,892	27,753	36,763	30,618
Reversal of valuation allowance	'	9,053	'	'
Unrecognized tax benefits current liability	1,218	'	'	'
Recognized interest and penalties in the consolidated statements of operations	-661	441	307	'
Accrued interest and penalties included in the consolidated balance sheets	1,344	1,952	'	'
Additional income taxes payable after settlement	2,614	'	'	'
Reduction in income tax provision	572	'	'	'
Reduction in previously unrecognized tax benefits	2,215	'	'	'
Domestic Jurisdiction	'	'	'	'
Valuation Allowance [Line Items]	'	'	'	'
Valuation allowance for deferred tax assets	27,355	'	'	'
Reversal of valuation allowance	'	9,053	'	'
Net operating loss carry forwards	43,872	'	'	'
State Jurisdiction	'	'	'	'
Valuation Allowance [Line Items]	'	'	'	'
Net operating loss carry forwards	73,939	'	'	'
Foreign Jurisdiction	'	'	'	'
Valuation Allowance [Line Items]	'	'	'	'
Undistributed earnings of foreign subsidiaries not reinvested	25,000	'	'	'
Amount of foreign withholding tax	3,160	'	'	'
Valuation allowance for deferred tax assets	5,537	'	'	'
Net operating loss carry forwards	$26,456	'	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Future minimum lease commitments (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified	Jun. 30, 2014
Capital leases	'
2015	$81
2016	21
2017	8
2018	'
2019	'
Thereafter	'
Total minimum lease payments	110
Amounts representing interest	-16
Present value of minimum lease payments	94
Non-cancellable operating leases	'
2015	4,486
2016	4,033
2017	3,696
2018	3,059
2019	2,641
Thereafter	4,668
Total minimum lease payments	$22,583

Commitments_and_Contingencies_2

Commitments and Contingencies (Detail Textuals) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
	Party	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Commitments And Contingencies [Line Items]	'	'	'	'	'
Operating leases, rent expense	'	'	$6,958	$6,084	$6,085
Number of potentially responsible parties	140	'	'	'	'
Term of employment and severance agreement	'	'	'up to 15 months	'	'
Loss on insurance claim	'	-5,350	'	'	'
Current And Long term Liabilities	'	'	'	'	'
Commitments And Contingencies [Line Items]	'	'	'	'	'
Accrual for environmental loss contingencies payments	'	'	7,273	8,292	'
C.P. Chemicals, Inc.	'	'	'	'	'
Commitments And Contingencies [Line Items]	'	'	'	'	'
Rate of investigation and remediation	'	'	50.00%	'	'
Environmental remediation expense	'	'	$175	'	'
Vulcan Corp.	'	'	'	'	'
Commitments And Contingencies [Line Items]	'	'	'	'	'
Rate of investigation and remediation	'	'	50.00%	'	'

Derivatives_Details

Derivatives (Details) (Options, Cash flow hedges)	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Brazilian Real calls	Brazilian Real calls	Brazilian Real calls	Brazilian Real puts	Brazilian Real puts	Brazilian Real puts
	BRL	Level 2	Level 2	BRL	Level 2	Level 2
		USD ($)	USD ($)		USD ($)	USD ($)
Derivative [Line Items]	'	'	'	'	'	'
Notional amount	78,000	'	'	-78,000	'	'
Fair value	'	$432	$365	'	($46)	($1,004)

Derivatives_Detail_Textuals

Derivatives (Detail Textuals) (Options, Cash flow hedges, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Derivative [Line Items]	'
Unrecognized gains (losses) on derivative instruments recorded in earnings within the next twelve months	$386
Other comprehensive income (loss)	'
Derivative [Line Items]	'
Unrecognized gains (losses) on derivative instruments	$386

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long-term debt	$286,422	$297,666
Fair values \| Term B Loan	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt fair value	289,638	'
Fair values \| Senior notes	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt fair value	'	322,500
Fair values \| Mayflower	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt fair value	'	26,968
Fair values \| BFI	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt fair value	'	$10,644

Fair_Value_Measurements_Detail1

Fair Value Measurements (Detail Textuals) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Fair Value Disclosures [Abstract]	'	'
Contract value of letters of credit	$17,140	$14,954

Business_Segments_Details

Business Segments (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$183,677	$173,267	$172,742	$162,228	$164,201	$162,685	$164,159	$162,106	$691,914	$653,151	$654,101
Adjusted EBITDA	24,245	22,444	22,310	21,598	19,651	19,420	18,778	17,905	90,597	75,754	'
Depreciation and amortization	'	'	'	'	'	'	'	'	21,453	19,023	17,527
Loss on insurance claim	-5,350	'	'	'	'	'	'	'	'	'	'
Foreign currency gains (losses), net	335	-275	-1,165	-648	-1,971	-838	-126	-168	-1,753	-3,103	-1,192
Loss on extinguishment of debt	-22,771	'	'	'	'	'	'	'	-22,771	'	'
Other income (expense), net	'	'	'	'	377	-482	-58	12	'	-151	400
Income before income taxes	-16,143	8,303	7,134	7,014	4,337	4,266	5,017	4,228	6,308	17,848	13,114
Identifiable assets	472,323	'	'	'	474,142	'	'	'	472,323	474,142	'
Animal Health	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	114,108	107,808	107,966	101,171	100,694	93,883	94,236	96,128	431,053	384,941	'
Adjusted EBITDA	26,146	25,505	24,522	24,107	23,044	20,334	19,516	20,103	100,280	82,997	'
Mineral Nutrition	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	54,879	49,901	50,633	46,186	48,728	51,757	52,892	49,792	201,599	203,169	'
Adjusted EBITDA	3,491	2,807	2,878	2,460	2,765	3,439	3,175	2,690	11,636	12,069	'
Performance Products	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	14,690	15,558	14,143	14,871	14,779	17,045	17,031	16,186	59,262	65,041	'
Adjusted EBITDA	1,521	906	1,103	1,096	-1,621	1,577	1,826	1,145	4,626	2,927	'
Operating Segments	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	691,914	653,151	654,101
Adjusted EBITDA	'	'	'	'	'	'	'	'	90,597	75,754	66,852
Depreciation and amortization	'	'	'	'	'	'	'	'	-21,453	-19,023	-17,527
Loss on insurance claim	'	'	'	'	'	'	'	'	-5,350	'	'
Interest expense, net	'	'	'	'	'	'	'	'	-32,962	-35,629	-35,419
Foreign currency gains (losses), net	'	'	'	'	'	'	'	'	-1,753	-3,103	-1,192
Loss on extinguishment of debt	'	'	'	'	'	'	'	'	-22,771	'	'
Other income (expense), net	'	'	'	'	'	'	'	'	'	-151	400
Income before income taxes	'	'	'	'	'	'	'	'	6,308	17,848	13,114
Identifiable assets	472,323	'	'	'	474,142	'	'	'	472,323	474,142	'
Operating Segments \| Animal Health	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	431,053	384,941	375,167
Adjusted EBITDA	'	'	'	'	'	'	'	'	100,280	82,997	70,456
Identifiable assets	361,376	'	'	'	329,323	'	'	'	361,376	329,323	'
Operating Segments \| Mineral Nutrition	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	201,599	203,169	210,091
Adjusted EBITDA	'	'	'	'	'	'	'	'	11,636	12,069	13,007
Identifiable assets	57,460	'	'	'	64,719	'	'	'	57,460	64,719	'
Operating Segments \| Performance Products	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	59,262	65,041	68,843
Adjusted EBITDA	'	'	'	'	'	'	'	'	4,626	2,927	5,132
Identifiable assets	23,429	'	'	'	21,233	'	'	'	23,429	21,233	'
Corporate	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	-25,945	-22,239	-21,743
Identifiable assets	$30,058	'	'	'	$58,867	'	'	'	$30,058	$58,867	'

Business_Segments_Detail_Textu

Business Segments (Detail Textuals) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
	Segment	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'
Equity method investments	$5,619	$3,515
Number of reportable segments	3	'
Animal Health	'	'
Segment Reporting Information [Line Items]	'	'
Equity method investments	5,140	4,734
Performance Products	'	'
Segment Reporting Information [Line Items]	'	'
Equity method investments	$479	$275

Geographic_Information_Details

Geographic Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	$183,677	$173,267	$172,742	$162,228	$164,201	$162,685	$164,159	$162,106	$691,914	$653,151	$654,101
United States	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	'	'	'	'	'	'	'	'	435,414	414,768	424,373
Israel	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	'	'	'	'	'	'	'	'	89,739	93,248	101,301
Latin America and Canada	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	'	'	'	'	'	'	'	'	84,775	68,575	61,407
Europe and Africa	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	'	'	'	'	'	'	'	'	38,563	32,501	30,087
Asia/Pacific	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	'	'	'
Total net sales	'	'	'	'	'	'	'	'	$43,423	$44,059	$36,933

Geographic_Information_Details1

Geographic Information (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Property, plant and equipment, net	$109,159	$104,422
United States	'	'
Property, plant and equipment, net	40,926	40,601
Israel	'	'
Property, plant and equipment, net	33,426	30,837
Brazil	'	'
Property, plant and equipment, net	32,946	30,988
Other	'	'
Property, plant and equipment, net	$1,861	$1,996

Selected_Quarterly_Results_of_2

Selected Quarterly Results of Operations Data (Unaudited) - Consolidating statement of operations (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total net sales	$183,677	$173,267	$172,742	$162,228	$164,201	$162,685	$164,159	$162,106	$691,914	$653,151	$654,101
Cost of goods sold	129,412	120,425	121,586	112,716	116,045	116,929	120,973	120,240	484,139	474,187	489,962
Gross profit	54,265	52,842	51,156	49,512	48,156	45,756	43,186	41,866	207,775	178,964	164,139
Selling, general and administrative expenses	41,208	35,520	34,138	33,115	33,251	31,295	29,030	28,657	143,981	122,233	114,814
Operating income (loss)	13,057	17,322	17,018	16,397	14,905	14,461	14,156	13,209	63,794	56,731	49,325
Interest expense	6,705	8,810	8,787	8,779	9,008	8,901	8,969	8,893	33,081	35,771	'
Interest (income)	59	-66	-68	-44	-34	-26	-14	-68	-119	-142	-281
Foreign currency (gains) losses, net	-335	275	1,165	648	1,971	838	126	168	1,753	3,103	1,192
Loss on extinguishment of debt	22,771	'	'	'	'	'	'	'	22,771	'	'
Other (income) expense, net	'	'	'	'	-377	482	58	-12	'	151	-400
Income (loss) before income taxes	-16,143	8,303	7,134	7,014	4,337	4,266	5,017	4,228	6,308	17,848	13,114
Provision (benefit) for income taxes	1,499	1,933	4,832	1,171	-1,642	86	-7,056	1,569	9,435	-7,043	6,138
Net income (loss)	-17,642	6,370	2,302	5,843	5,979	4,180	12,073	2,659	-3,127	24,891	6,976
Net income (loss) per share-basic and diluted (in dollars per share)	($0.47)	$0.21	$0.08	$0.19	$0.20	$0.14	$0.40	$0.09	($0.10)	$0.82	$0.23
Adjusted EBITDA	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	24,245	22,444	22,310	21,598	19,651	19,420	18,778	17,905	90,597	75,754	'
Animal Health	'	'	'	'	'	'	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total net sales	114,108	107,808	107,966	101,171	100,694	93,883	94,236	96,128	431,053	384,941	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	26,146	25,505	24,522	24,107	23,044	20,334	19,516	20,103	100,280	82,997	'
Mineral Nutrition	'	'	'	'	'	'	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total net sales	54,879	49,901	50,633	46,186	48,728	51,757	52,892	49,792	201,599	203,169	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	3,491	2,807	2,878	2,460	2,765	3,439	3,175	2,690	11,636	12,069	'
Performance Products	'	'	'	'	'	'	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total net sales	14,690	15,558	14,143	14,871	14,779	17,045	17,031	16,186	59,262	65,041	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	1,521	906	1,103	1,096	-1,621	1,577	1,826	1,145	4,626	2,927	'
Corporate	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	'	'	'	'	'	'	'	'	'	'	'
Adjusted EBITDA	($6,913)	($6,774)	($6,193)	($6,065)	($4,537)	($5,930)	($5,739)	($6,033)	($25,945)	($22,239)	'